No definition available.
Malignant neoplasm of accessory sinuses, including Hilmo
C3_ACCESSORY_SINUS_WIDE
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleNone |
519870 |
2. Check conditionsNone |
519870 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
177 |
4. Check minimum number of eventsNone |
177 |
5. Include endpointsNone |
177 |
6. Filter based on genotype QC (FinnGen only) |
171 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of accessory sinuses, including Hilmo
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of nasal cavity and sinuses, including Hilmo
- Malignant neoplasm of respiratory system and intrathoracic organs, including Hilmo
- Solid cancers, including Hilmo
- Malignant neoplasm, wide definition
- Malignant neoplasm, including Hilmo
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded (different definition than used in FinnGen).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 171 | 65 | 106 |
| Unadjusted period prevalence (%) | 0.04 | 0.02 | 0.05 |
| Median age at first event (years) | 63.81 | 61.31 | 65.35 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 177
- Matched controls
- 1770
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
130
Kela drug reimbursment
Malignant tumour
+∞
71.9
64
*
C31.0
ICD-10 Finland
Malignant neoplasm: Maxillary sinus
+∞
59.8
54
*
XX3DW
NOMESCO Finland
Time consuming IT work
18.1
46.6
41
29
H02AB02
ATC
dexamethasone; systemic
79.2
42.8
47
8
C30.0
ICD-10 Finland
Malignant neoplasm: Nasal cavity
+∞
42.4
39
*
UDH02
NOMESCO Finland
Rhinopharyngoscopy
11.5
40.8
49
57
WF002
NOMESCO Finland
Radical radiotherapy
474.3
39.7
38
*
A03FA01
ATC
metoclopramide; systemic, rectal
8.2
37.0
63
112
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
33.4
31
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
33.4
31
*
C31.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of accessory sinuses
+∞
31.2
29
*
N02AA05
ATC
oxycodone; systemic
6.4
29.9
66
150
WZC00
NOMESCO Finland
Treatment plan or consultation
5.5
28.5
88
269
C31.9
ICD-10 Finland
Malignant neoplasm: Accessory sinus, unspecified
+∞
27.8
26
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
316.4
27.5
27
*
A04AA02
ATC
granisetron; systemic, transdermal
316.4
27.5
27
*
Z51.5
ICD-10 Finland
Palliative care
10.3
26.3
32
37
YA1AD
NOMESCO Finland
CT examination of head and neck for dose design of radiotherapy
+∞
25.6
24
*
C31.1
ICD-10 Finland
Malignant neoplasm: Ethmoidal sinus
+∞
24.5
23
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
262.6
23.2
23
*
D14.0
ICD-10 Finland
Benign neoplasm: Middle ear, nasal cavity and accessory sinuses
45.1
22.5
27
7
D38.51
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour of other accessory sinus
+∞
21.3
20
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
21.3
20
*
UDM02
NOMESCO Finland
Sinoscopy
25.3
20.2
28
13
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
+∞
20.2
19
*
8070/3-C31.0
ICD-O-3
Squamous cell carcinoma, NOS, of maxillary sinus
+∞
20.2
19
*
DMB20
NOMESCO Finland
Functional endoscopic opening of maxillary antrum
8.7
19.7
27
36
A04AA01
ATC
ondansetron; systemic, rectal
24.2
19.3
27
13
DM1DG
NOMESCO Finland
Paranasal sinuses and face area very extensive MRI examination with high intensity magnet
+∞
19.1
18
*
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
28.8
18.8
25
10
DHA10
NOMESCO Finland
Biopsy of cavity of nose
32.7
17.9
23
8
JN4BD
NOMESCO Finland
Extensive body CT
8.4
17.9
25
34
YA1VG
NOMESCO Finland
MRI examination of head and neck with high intesity magnet for dose design of radiotherapy
+∞
16.9
16
*
C83.31
ICD-10 Finland
Diffuse lymphoma with large B cells
+∞
16.9
16
*
L03AA13
ATC
pegfilgrastim; parenteral
186.9
16.8
17
*
JDB10
NOMESCO Finland
Percutaneous gastrostomy
66.3
16.1
18
*
R04.0
ICD-10 Finland
Epistaxis
5.2
15.0
35
80
EN1BD
NOMESCO Finland
Very extensive CT examination of mouth and soft tissues of neck
87.6
14.8
16
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
14.8
14
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
14.8
14
*
EP1CG
NOMESCO Finland
Extensive MRI examination of soft tissue of neck with high intesity magnet
39.8
14.7
18
5
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
162.9
14.7
15
*
A07AA02
ATC
nystatin; oral
6.6
13.9
24
41
DM1BD
NOMESCO Finland
Extensive CT of paranasal sinuses and face area
81.2
13.8
15
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
20.3
13.7
20
11
ZZQ00
NOMESCO Finland
Free microvascular graft of skin
+∞
13.7
13
*
D38.50
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour of maxillary sinus
+∞
13.7
13
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
151.1
13.6
14
*
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
43.7
13.4
16
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
12.6
12
*
L03AA02
ATC
filgrastim; parenteral
139.5
12.6
13
*
DMA00
NOMESCO Finland
Biopsy of maxillary antrum
139.5
12.6
13
*
DPA30
NOMESCO Finland
Sphenotomy
40.7
12.4
15
*
WZC30
NOMESCO Finland
Teaching
4.2
12.2
38
109
EBB10
NOMESCO Finland
Insertion of dental implant
32.5
11.8
15
5
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
69.7
11.8
13
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
69.7
11.8
13
*
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
+∞
11.6
11
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
11.6
11
*
EEB10
NOMESCO Finland
Maxillectomy
+∞
11.6
11
*
A04AD12
ATC
aprepitant; systemic
+∞
11.6
11
*
EEB00
NOMESCO Finland
Partial excision of maxilla
128.0
11.6
12
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
128.0
11.6
12
*
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
14.0
11.4
19
15
GBB00
NOMESCO Finland
Tracheostomy
21.8
11.4
16
8
WX402
NOMESCO Finland
General anaesthesia
3.5
11.2
46
160
K08.1
ICD-10 Finland
Loss of teeth due to accident, extraction or local periodontal disease
3.9
10.9
37
113
D70.82
ICD-10 Finland
Drug-induced neutropenia
116.6
10.5
11
*
PJD81
NOMESCO Finland
Excision of lymph nodes from upper part of neck
+∞
10.5
10
*
AAE99
NOMESCO Finland
Other operation by cranial base approach
+∞
10.5
10
*
DM1CG
NOMESCO Finland
Paranasal sinuses and face area extensive MRI examination with high intensity magnet
+∞
10.5
10
*
SAA03
NOMESCO Finland
Extended examination of mouth
2.8
10.2
79
394
DM1AD
NOMESCO Finland
CT of paranasal sinuses and face area
8.2
10.1
22
30
ZXE40
NOMESCO Finland
More than seven and less than nine hours
27.9
10.0
13
5
EBB11
NOMESCO Finland
Insertion of additional dental implant in one session
58.3
9.8
11
*
GD6AD
NOMESCO Finland
CT of chest and neck
58.3
9.8
11
*
SBB10
NOMESCO Finland
Dental impressions
5.0
9.6
22
49
ZX120
NOMESCO Finland
Intravenous
5.2
9.6
21
45
DNB20
NOMESCO Finland
Endoscopic ethmoidectomy
11.6
9.5
17
16
EN1AD
NOMESCO Finland
CT examination of mouth and soft tissues of neck
23.2
9.5
13
6
ZX095
NOMESCO Finland
Combined chemoradiotherapy
+∞
9.5
9
*
A79
ICPC
Malignancy NOS
+∞
9.5
9
*
DMB30
NOMESCO Finland
Transmaxillary excision of lesion of maxillary antrum
+∞
9.5
9
*
116
Kela drug reimbursment
Prostate cancer
+∞
9.5
9
*
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
8.2
9.2
20
27
WX105
NOMESCO Finland
Surface analgesia on skin or mucosa
3.9
9.1
29
84
ZXC95
NOMESCO Finland
Use of surgical navigator
25.6
9.0
12
5
WW500
NOMESCO Finland
Blood transfusion
10.9
8.7
16
16
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
4.7
8.7
21
49
R22.0
ICD-10 Finland
Localized swelling, mass and lump, head
9.3
8.5
17
20
EP1AE
NOMESCO Finland
Neck ultrasound examination
7.7
8.5
19
27
ZZF00
NOMESCO Finland
Graft of adipose tissue
94.4
8.5
9
*
ZZC00
NOMESCO Finland
Graft of fascia
94.4
8.5
9
*
8090/3-C44.3
ICD-O-3
Basal cell carcinoma, NOS, of skin of other and unspecified parts of face
+∞
8.4
8
*
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
8.4
8
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
8.4
8
*
ZZQ20
NOMESCO Finland
Free microvascular graft of skin, muscle and bone
+∞
8.4
8
*
DNB30
NOMESCO Finland
Excision of lesion of ethmoidal sinus
+∞
8.4
8
*
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
+∞
8.4
8
*
SPA10
NOMESCO Finland
Setting attachments on tooth or implanted bracket or imblant based structures
+∞
8.4
8
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
+∞
8.4
8
*
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
8.4
8
*
C03.0
ICD-10 Finland
Malignant neoplasm: Upper gum
+∞
8.4
8
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.5
8.4
32
105
EBB15
NOMESCO Finland
Insertion of dental implant abutment
35.1
8.2
10
*
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
47.1
7.8
9
*
DHB40
NOMESCO Finland
Conchotomy
47.1
7.8
9
*
SPF20
NOMESCO Finland
Temporary relining of dentures
47.1
7.8
9
*
R4190
NOMESCO Finland
Nutritional therapy
12.6
7.7
13
11
WX408
NOMESCO Finland
General anesthesy, balanced
2.7
7.5
49
219
L02AE02
ATC
leuprorelin; implant, parenteral
83.4
7.5
8
*
DPB00
NOMESCO Finland
Partial excision of frontal sinus
83.4
7.5
8
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.8
7.5
44
186
DCA20
NOMESCO Finland
Insertion of ventilating tube through tympanic membrane
10.0
7.4
14
15
8720/3-C30.0
ICD-O-3
Malignant melanoma, NOS, of nasal cavity
+∞
7.3
7
*
1600A
ICD-9 Finland
Malignant neoplasm of nasal cavities, middle ear and accessory sinuses, Nasal cavities
+∞
7.3
7
*
EP1DG
NOMESCO Finland
Very extensive examination of soft tissue of neck with high intesity magnet
+∞
7.3
7
*
DJB10
NOMESCO Finland
Excision of septum of nose
+∞
7.3
7
*
ZZR00
NOMESCO Finland
Flap of skin
+∞
7.3
7
*
DKW40
NOMESCO Finland
Ligature of artery of internal nose
+∞
7.3
7
*
C31.3
ICD-10 Finland
Malignant neoplasm: Sphenoidal sinus
+∞
7.3
7
*
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
+∞
7.3
7
*
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
+∞
7.3
7
*
AAG50
NOMESCO Finland
Stereotactic intracranial radiotherapy
+∞
7.3
7
*
C34.1
ICD-10 Finland
Malignant neoplasm: Upper lobe, bronchus or lung
+∞
7.3
7
*
C83.3
ICD-10 Finland
Diffuse large B-cell lymphoma
+∞
7.3
7
*
JN4AD
NOMESCO Finland
Body CT examination
4.2
7.2
20
52
TPX10
NOMESCO Finland
Implantation of vascular injection port
12.8
7.2
12
10
SBB00
NOMESCO Finland
Clinical photography of mouth and teeth
10.7
7.2
13
13
ZXE50
NOMESCO Finland
More than nine and less than 12 hours
14.5
7.0
11
8
TPH07
NOMESCO Finland
Cathetrisation of artery
3.4
6.8
27
90
EB1BI
NOMESCO Finland
Cone beam imaging of teeth and jaws (1–2 quarters)
17.5
6.8
10
6
CCD60
NOMESCO Finland
Transnasal dacryocystorhinostomy
41.7
6.8
8
*
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
3.3
6.7
27
91
EBA15
NOMESCO Finland
Extraction of multiple teeth
6.7
6.6
16
26
ZXE00
NOMESCO Finland
One hour or less
2.3
6.5
71
399
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
6.4
6.5
16
27
EP1BG
NOMESCO Finland
MRI examination of soft tissue of neck with high intesity magnet
72.3
6.5
7
*
QA4S1
NOMESCO Finland
Photography of skin or subcutaneous tissue in face
72.3
6.5
7
*
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
2.3
6.4
76
442
XW000
NOMESCO Finland
Bone marrow biopsy
9.8
6.4
12
13
ZXE60
NOMESCO Finland
More than 12 and less than 15 hours
18.9
6.3
9
5
XZZ00
NOMESCO Finland
Active surveillance of a diagnosed cancer
+∞
6.3
6
*
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
6.3
6
*
QAB05
NOMESCO Finland
Revision of wound of skin of head or neck
+∞
6.3
6
*
8070/3-C30.0
ICD-O-3
Squamous cell carcinoma, NOS, of nasal cavity
+∞
6.3
6
*
ZX080
NOMESCO Finland
Image guided radiotherapy
+∞
6.3
6
*
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
+∞
6.3
6
*
PJD71
NOMESCO Finland
Extended sparing excision of cervical lymph nodes
+∞
6.3
6
*
YA1CD
NOMESCO Finland
Very extensive CT examination of head and neck for dose design of radiotherapy
+∞
6.3
6
*
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
+∞
6.3
6
*
CAD00
NOMESCO Finland
Exenteration of orbit with use of graft or flap
+∞
6.3
6
*
8720/3-C31.0
ICD-O-3
Malignant melanoma, NOS, of maxillary sinus
+∞
6.3
6
*
C90.2
ICD-10 Finland
Extramedullary plasmacytoma
+∞
6.3
6
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
6.3
6
*
EEB20
NOMESCO Finland
Hemimaxillectomy
+∞
6.3
6
*
QA1S1
NOMESCO Finland
Photography of skin or subcutaneous tissue in head
+∞
6.3
6
*
TJD20
NOMESCO Finland
Change of gastrostomy tube
+∞
6.3
6
*
L02BB03
ATC
bicalutamide; oral
+∞
6.3
6
*
C11.9
ICD-10 Finland
Malignant neoplasm: Nasopharynx, unspecified
+∞
6.3
6
*
UDQ12
NOMESCO Finland
Flexible laryngoscopy
3.9
6.2
19
53
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
5.6
6.2
17
33
QAE99
NOMESCO Finland
Other excision or repair surgery of skin and subcutaneous tissue in head and neck
13.1
6.2
10
8
WZC10
NOMESCO Finland
Written specialist consultation based on a referral from a dentist or a physician
5.8
6.0
16
30
TimeCodeWAS
↥TODO / Current known limitations:
- Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
- Legend / how to read the glyphs.
- Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
- Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
- Download CSV.
- No filters and sorters.
- Limited amount of endpoints (~400) having TimeCodeWAS data.
- Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Otolaryngology
4 [38004449]
4 [38004449]
1.1e+00
2.2e+00
4.8e+00
1.0e+50
5.5e+00
3.9e+00
2.9e+00
cases:23.46%
controls:9.01%
cases:24.69%
controls:3.42%
cases:35.80%
controls:0.44%
cases:42.59%
controls:0.00%
cases:51.57%
controls:0.44%
cases:63.85%
controls:3.52%
cases:62.22%
controls:8.67%
38
145
124
1464
40
55
122
1554
58
7
104
1602
69
0
93
1609
82
7
77
1600
83
55
47
1508
56
118
34
1243
Outpatient Visit
OP [9202]
OP [9202]
1.5e-01
5.7e-01
2.1e+00
4.4e+00
2.4e+00
1.8e+00
8.7e-01
cases:69.14%
controls:65.76%
cases:58.02%
controls:43.94%
cases:41.36%
controls:8.14%
cases:32.72%
controls:0.62%
cases:55.97%
controls:10.14%
cases:83.08%
controls:45.87%
cases:86.67%
controls:73.11%
112
1058
50
551
94
707
68
902
67
131
95
1478
53
10
109
1599
89
163
70
1444
108
717
22
846
78
995
12
366
Treatment plan or consultation
WZC00 [2001310885]
WZC00 [2001310885]
1.1e+00
1.2e+00
—
—
3.8e+00
3.7e+00
2.0e+00
cases:8.64%
controls:3.17%
cases:4.94%
controls:1.62%
—
—
—
—
cases:12.58%
controls:0.31%
cases:31.54%
controls:1.15%
cases:23.33%
controls:3.97%
14
51
148
1558
8
26
154
1583
—
—
20
5
139
1602
41
18
89
1545
21
54
69
1307
Outpatient Hospital
22 [8756]
22 [8756]
3.7e-01
1.1e+00
2.6e+00
—
3.3e+00
2.1e+00
1.0e+00
cases:32.72%
controls:25.11%
cases:17.90%
controls:6.71%
cases:9.88%
controls:0.81%
—
—
cases:21.38%
controls:1.00%
cases:35.38%
controls:6.01%
cases:34.44%
controls:16.24%
53
404
109
1205
29
108
133
1501
16
13
146
1596
—
34
16
125
1591
46
94
84
1469
31
221
59
1140
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
890-4 [3001079]
7.2e-01
6.8e-01
2.8e+00
—
3.8e+00
2.3e+00
1.1e+00
cases:11.11%
controls:5.72%
cases:6.17%
controls:3.23%
cases:7.41%
controls:0.50%
—
—
cases:13.84%
controls:0.37%
cases:20.00%
controls:2.43%
cases:22.22%
controls:8.52%
18
92
144
1517
10
52
152
1557
12
8
150
1601
—
22
6
137
1601
26
38
104
1525
20
116
70
1245
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
14631-6 [3006140]
5.0e-01
9.0e-01
2.0e+00
—
3.8e+00
2.3e+00
1.1e+00
cases:13.58%
controls:8.70%
cases:10.49%
controls:4.54%
cases:6.79%
controls:0.99%
—
—
cases:20.13%
controls:0.56%
cases:32.31%
controls:4.48%
cases:28.89%
controls:11.83%
22
140
140
1469
17
73
145
1536
11
16
151
1593
—
32
9
127
1598
42
70
88
1493
26
161
64
1200
Office Visit
OMOP4822458 [581477]
OMOP4822458 [581477]
1.8e-01
9.8e-01
2.9e+00
—
3.2e+00
2.9e+00
5.9e-01
cases:10.49%
controls:8.95%
cases:7.41%
controls:2.92%
cases:6.17%
controls:0.37%
—
—
cases:10.06%
controls:0.44%
cases:26.92%
controls:1.98%
cases:11.11%
controls:6.47%
17
144
145
1465
12
47
150
1562
10
6
152
1603
—
16
7
143
1600
35
31
95
1532
10
88
80
1273
dexamethasone; oral, parenteral
H02AB02 [21602730]
H02AB02 [21602730]
1.3e+00
2.3e+00
—
—
1.0e+50
3.9e+00
2.2e+00
cases:3.70%
controls:1.06%
cases:4.94%
controls:0.50%
—
—
—
—
cases:6.29%
controls:0.00%
cases:17.69%
controls:0.45%
cases:15.56%
controls:1.91%
6
17
156
1592
8
8
154
1601
—
—
10
0
149
1607
23
7
107
1556
14
26
76
1335
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
14682-9 [3020564]
7.4e-02
2.8e-01
1.9e+00
3.3e+00
2.2e+00
8.7e-01
2.1e-01
cases:32.10%
controls:30.52%
cases:32.72%
controls:26.91%
cases:26.54%
controls:5.34%
cases:8.02%
controls:0.31%
cases:33.96%
controls:5.29%
cases:49.23%
controls:28.92%
cases:50.00%
controls:44.82%
52
491
110
1118
53
433
109
1176
43
86
119
1523
13
5
149
1604
54
85
105
1522
64
452
66
1111
45
610
45
751
Inpatient Hospital
21 [8717]
21 [8717]
3.7e-01
5.2e-01
2.4e+00
1.0e+50
3.0e+00
1.7e+00
7.6e-01
cases:41.36%
controls:32.75%
cases:19.14%
controls:12.37%
cases:15.43%
controls:1.68%
cases:14.81%
controls:0.00%
cases:30.82%
controls:2.12%
cases:40.77%
controls:10.68%
cases:40.00%
controls:23.81%
67
527
95
1082
31
199
131
1410
25
27
137
1582
24
0
138
1609
49
34
110
1573
53
167
77
1396
36
324
54
1037
Infiltration anesthesia
WX110 [2001310767]
WX110 [2001310767]
3.4e-01
4.6e-01
2.3e+00
1.0e+50
2.7e+00
1.9e+00
8.7e-01
cases:20.99%
controls:15.85%
cases:8.64%
controls:5.66%
cases:4.94%
controls:0.50%
cases:4.32%
controls:0.00%
cases:11.32%
controls:0.81%
cases:25.38%
controls:4.67%
cases:33.33%
controls:17.34%
34
255
128
1354
14
91
148
1518
8
8
154
1601
7
0
155
1609
18
13
141
1594
33
73
97
1490
30
236
60
1125
Plastic And Reconstructive Surgery
24 [38004467]
24 [38004467]
9.0e-01
2.2e+00
—
—
—
3.3e+00
2.4e+00
cases:4.32%
controls:1.80%
cases:4.32%
controls:0.50%
—
—
—
—
—
—
cases:9.23%
controls:0.38%
cases:15.56%
controls:1.62%
7
29
155
1580
7
8
155
1601
—
—
—
12
6
118
1557
14
22
76
1339
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
14749-6 [3013826]
1.5e-01
5.8e-01
2.7e+00
—
3.3e+00
1.7e+00
5.8e-01
cases:12.35%
controls:10.81%
cases:10.49%
controls:6.15%
cases:9.88%
controls:0.75%
—
—
cases:9.43%
controls:0.37%
cases:23.08%
controls:5.44%
cases:24.44%
controls:15.36%
20
174
142
1435
17
99
145
1510
16
12
146
1597
—
15
6
144
1601
30
85
100
1478
22
209
68
1152
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
751-8 [3013650]
3.8e-01
6.1e-01
1.9e+00
—
2.5e+00
1.7e+00
1.0e+00
cases:13.58%
controls:9.70%
cases:12.96%
controls:7.46%
cases:11.73%
controls:1.86%
—
—
cases:18.87%
controls:1.87%
cases:32.31%
controls:7.81%
cases:33.33%
controls:15.06%
22
156
140
1453
21
120
141
1489
19
30
143
1579
—
30
30
129
1577
42
122
88
1441
30
205
60
1156
cefalexin; oral
J01DB01 [21602870]
J01DB01 [21602870]
2.0e-01
7.1e-01
2.1e+00
—
2.2e+00
2.0e+00
9.1e-01
cases:27.78%
controls:23.99%
cases:14.81%
controls:7.89%
cases:4.94%
controls:0.62%
—
—
cases:9.43%
controls:1.18%
cases:39.23%
controls:8.25%
cases:44.44%
controls:24.39%
45
386
117
1223
24
127
138
1482
8
10
154
1599
—
15
19
144
1588
51
129
79
1434
40
332
50
1029
MCH [Entitic mass]
28539-5 [3035941]
28539-5 [3035941]
-3.8e-02
2.0e-01
1.5e+00
3.0e+00
1.9e+00
7.1e-01
1.3e-01
cases:32.10%
controls:32.94%
cases:33.33%
controls:29.02%
cases:24.07%
controls:6.40%
cases:6.79%
controls:0.37%
cases:31.45%
controls:6.16%
cases:47.69%
controls:31.03%
cases:50.00%
controls:46.88%
52
530
110
1079
54
467
108
1142
39
103
123
1506
11
6
151
1603
50
99
109
1508
62
485
68
1078
45
638
45
723
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
30428-7 [3024731]
-4.1e-02
2.0e-01
1.5e+00
3.0e+00
1.9e+00
7.1e-01
1.3e-01
cases:32.10%
controls:33.00%
cases:33.33%
controls:29.09%
cases:24.07%
controls:6.46%
cases:6.79%
controls:0.37%
cases:31.45%
controls:6.22%
cases:47.69%
controls:30.97%
cases:50.00%
controls:46.88%
52
531
110
1078
54
468
108
1141
39
104
123
1505
11
6
151
1603
50
100
109
1507
62
484
68
1079
45
638
45
723
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
26453-1 [3026361]
-4.1e-02
2.0e-01
1.5e+00
3.0e+00
1.9e+00
7.0e-01
1.3e-01
cases:32.10%
controls:33.00%
cases:33.33%
controls:29.09%
cases:24.07%
controls:6.46%
cases:6.79%
controls:0.37%
cases:31.45%
controls:6.22%
cases:47.69%
controls:31.09%
cases:50.00%
controls:46.88%
52
531
110
1078
54
468
108
1141
39
104
123
1505
11
6
151
1603
50
100
109
1507
62
486
68
1077
45
638
45
723
Platelets [#/volume] in Blood
26515-7 [3007461]
26515-7 [3007461]
-3.8e-02
2.0e-01
1.5e+00
3.0e+00
1.9e+00
7.0e-01
1.3e-01
cases:32.10%
controls:32.94%
cases:33.33%
controls:28.96%
cases:24.07%
controls:6.46%
cases:6.79%
controls:0.37%
cases:31.45%
controls:6.22%
cases:47.69%
controls:31.09%
cases:50.00%
controls:46.80%
52
530
110
1079
54
466
108
1143
39
104
123
1505
11
6
151
1603
50
100
109
1507
62
486
68
1077
45
637
45
724
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
20570-8 [3009542]
-4.1e-02
2.0e-01
1.5e+00
3.0e+00
1.9e+00
7.0e-01
1.3e-01
cases:32.10%
controls:33.00%
cases:33.33%
controls:29.09%
cases:24.07%
controls:6.46%
cases:6.79%
controls:0.37%
cases:31.45%
controls:6.22%
cases:47.69%
controls:31.16%
cases:50.00%
controls:46.80%
52
531
110
1078
54
468
108
1141
39
104
123
1505
11
6
151
1603
50
100
109
1507
62
487
68
1076
45
637
45
724
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
718-7 [3000963]
-1.3e-02
2.0e-01
1.5e+00
3.0e+00
1.9e+00
7.0e-01
1.3e-01
cases:32.72%
controls:33.00%
cases:33.33%
controls:29.15%
cases:24.07%
controls:6.46%
cases:6.79%
controls:0.37%
cases:31.45%
controls:6.22%
cases:47.69%
controls:31.16%
cases:50.00%
controls:46.88%
53
531
109
1078
54
469
108
1140
39
104
123
1505
11
6
151
1603
50
100
109
1507
62
487
68
1076
45
638
45
723
Leukocytes [#/volume] in Blood
26464-8 [3010813]
26464-8 [3010813]
-4.4e-02
2.0e-01
1.5e+00
3.0e+00
1.9e+00
7.0e-01
1.2e-01
cases:32.10%
controls:33.06%
cases:33.33%
controls:29.15%
cases:24.07%
controls:6.53%
cases:6.79%
controls:0.37%
cases:31.45%
controls:6.22%
cases:47.69%
controls:31.16%
cases:50.00%
controls:47.02%
52
532
110
1077
54
469
108
1140
39
105
123
1504
11
6
151
1603
50
100
109
1507
62
487
68
1076
45
640
45
721
Tissue Pathology biopsy report
66121-5 [40768804]
66121-5 [40768804]
1.0e+00
1.6e+00
1.0e+50
1.0e+50
—
2.9e+00
1.6e+00
cases:12.35%
controls:4.85%
cases:8.02%
controls:1.68%
cases:9.26%
controls:0.00%
cases:12.96%
controls:0.00%
—
—
cases:22.31%
controls:1.60%
cases:21.11%
controls:5.36%
20
78
142
1531
13
27
149
1582
15
0
147
1609
21
0
141
1609
—
29
25
101
1538
19
73
71
1288
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
6768-6 [3035995]
2.3e-01
5.1e-01
1.6e+00
—
2.9e+00
1.6e+00
8.9e-01
cases:19.14%
controls:15.79%
cases:16.05%
controls:10.32%
cases:9.26%
controls:1.99%
—
—
cases:20.13%
controls:1.37%
cases:36.92%
controls:10.56%
cases:38.89%
controls:20.72%
31
254
131
1355
26
166
136
1443
15
32
147
1577
—
32
22
127
1585
48
165
82
1398
35
282
55
1079
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
30385-9 [3002385]
1.1e-01
4.0e-01
1.4e+00
2.8e+00
1.9e+00
7.6e-01
-1.1e-02
cases:21.60%
controls:19.76%
cases:24.69%
controls:18.02%
cases:14.81%
controls:4.16%
cases:4.94%
controls:0.31%
cases:22.01%
controls:3.92%
cases:33.85%
controls:19.26%
cases:33.33%
controls:33.58%
35
318
127
1291
40
290
122
1319
24
67
138
1542
8
5
154
1604
35
63
124
1544
44
301
86
1262
30
457
60
904
Laboratory Visit
OMOP4822461 [32036]
OMOP4822461 [32036]
5.1e-03
1.7e-01
1.5e+00
3.7e+00
1.6e+00
5.7e-01
1.7e-02
cases:37.04%
controls:36.92%
cases:38.27%
controls:34.43%
cases:33.33%
controls:9.94%
cases:22.22%
controls:0.68%
cases:37.74%
controls:11.14%
cases:51.54%
controls:37.62%
cases:51.11%
controls:50.70%
60
594
102
1015
62
554
100
1055
54
160
108
1449
36
11
126
1598
60
179
99
1428
67
588
63
975
46
690
44
671
Supplier / Service Provider
OMOP5117446 [33004]
OMOP5117446 [33004]
-4.2e-01
-6.1e-01
—
—
—
3.9e+00
2.9e+00
cases:19.14%
controls:26.54%
cases:4.32%
controls:7.71%
—
—
—
—
—
—
cases:16.15%
controls:0.38%
cases:17.78%
controls:1.18%
31
427
131
1182
7
124
155
1485
—
—
—
21
6
109
1557
16
16
74
1345
Basophils/Leukocytes in Blood
30180-4 [3022096]
30180-4 [3022096]
1.6e-01
6.0e-01
2.0e+00
—
2.2e+00
1.6e+00
1.1e+00
cases:9.88%
controls:8.51%
cases:9.88%
controls:5.66%
cases:9.26%
controls:1.37%
—
—
cases:10.06%
controls:1.24%
cases:24.62%
controls:6.40%
cases:27.78%
controls:11.76%
16
137
146
1472
16
91
146
1518
15
22
147
1587
—
16
20
143
1587
32
100
98
1463
25
160
65
1201
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
26450-7 [3006504]
1.6e-01
6.0e-01
2.0e+00
—
2.2e+00
1.6e+00
1.0e+00
cases:9.88%
controls:8.58%
cases:9.88%
controls:5.66%
cases:9.26%
controls:1.37%
—
—
cases:10.06%
controls:1.24%
cases:24.62%
controls:6.40%
cases:27.78%
controls:11.98%
16
138
146
1471
16
91
146
1518
15
22
147
1587
—
16
20
143
1587
32
100
98
1463
25
163
65
1198
Monocytes/Leukocytes in Blood
26485-3 [3019069]
26485-3 [3019069]
1.4e-01
6.0e-01
2.0e+00
—
2.2e+00
1.5e+00
1.1e+00
cases:9.88%
controls:8.70%
cases:9.88%
controls:5.66%
cases:9.26%
controls:1.37%
—
—
cases:10.06%
controls:1.24%
cases:23.85%
controls:6.40%
cases:27.78%
controls:11.83%
16
140
146
1469
16
91
146
1518
15
22
147
1587
—
16
20
143
1587
31
100
99
1463
25
161
65
1200
Dentistry
C5 [903277]
C5 [903277]
1.4e+00
2.0e+00
—
—
—
4.0e+00
2.7e+00
cases:4.94%
controls:1.24%
cases:3.09%
controls:0.44%
—
—
—
—
—
—
cases:28.46%
controls:0.70%
cases:23.33%
controls:1.98%
8
20
154
1589
5
7
157
1602
—
—
—
37
11
93
1552
21
27
69
1334
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
57782-5 [40760892]
2.4e-01
8.9e-01
2.5e+00
—
2.5e+00
1.7e+00
5.9e-01
cases:4.32%
controls:3.42%
cases:5.56%
controls:2.36%
cases:4.32%
controls:0.37%
—
—
cases:4.40%
controls:0.37%
cases:12.31%
controls:2.56%
cases:10.00%
controls:5.80%
7
55
155
1554
9
38
153
1571
7
6
155
1603
—
7
6
152
1601
16
40
114
1523
9
79
81
1282
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
26478-8 [3002030]
6.1e-02
5.2e-01
2.0e+00
—
2.1e+00
1.5e+00
1.0e+00
cases:9.26%
controls:8.76%
cases:9.26%
controls:5.72%
cases:9.26%
controls:1.37%
—
—
cases:10.06%
controls:1.31%
cases:23.85%
controls:6.59%
cases:27.78%
controls:12.27%
15
141
147
1468
15
92
147
1517
15
22
147
1587
—
16
21
143
1586
31
103
99
1460
25
167
65
1194
Ophthalmology
18 [38004463]
18 [38004463]
6.2e-03
5.6e-01
1.9e+00
1.0e+50
2.0e+00
1.6e+00
1.1e+00
cases:15.43%
controls:15.35%
cases:11.73%
controls:7.02%
cases:8.64%
controls:1.43%
cases:3.09%
controls:0.00%
cases:8.81%
controls:1.31%
cases:27.69%
controls:7.10%
cases:40.00%
controls:18.37%
25
247
137
1362
19
113
143
1496
14
23
148
1586
5
0
157
1609
14
21
145
1586
36
111
94
1452
36
250
54
1111
Basophils [#/volume] in Blood
26444-0 [3006315]
26444-0 [3006315]
6.8e-02
4.9e-01
2.1e+00
—
2.1e+00
1.2e+00
9.9e-01
cases:9.26%
controls:8.70%
cases:9.88%
controls:6.28%
cases:9.88%
controls:1.37%
—
—
cases:10.06%
controls:1.31%
cases:20.77%
controls:7.10%
cases:28.89%
controls:13.15%
15
140
147
1469
16
101
146
1508
16
22
146
1587
—
16
21
143
1586
27
111
103
1452
26
179
64
1182
Monocytes [#/volume] in Blood
26484-6 [3001604]
26484-6 [3001604]
3.9e-04
4.9e-01
2.1e+00
—
2.1e+00
1.2e+00
9.9e-01
cases:8.64%
controls:8.64%
cases:9.88%
controls:6.28%
cases:9.88%
controls:1.37%
—
—
cases:10.06%
controls:1.31%
cases:20.00%
controls:7.04%
cases:28.89%
controls:13.08%
14
139
148
1470
16
101
146
1508
16
22
146
1587
—
16
21
143
1586
26
110
104
1453
26
178
64
1183
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
26511-6 [3018010]
6.5e-02
4.8e-01
2.0e+00
—
2.2e+00
1.3e+00
9.0e-01
cases:8.64%
controls:8.14%
cases:8.64%
controls:5.53%
cases:9.26%
controls:1.37%
—
—
cases:10.06%
controls:1.24%
cases:20.00%
controls:6.46%
cases:25.56%
controls:12.20%
14
131
148
1478
14
89
148
1520
15
22
147
1587
—
16
20
143
1587
26
101
104
1462
23
166
67
1195
Differential panel, method unspecified - Blood
69738-3 [42870588]
69738-3 [42870588]
5.7e-01
1.8e-01
1.7e+00
—
1.8e+00
1.6e+00
1.1e+00
cases:8.64%
controls:5.10%
cases:5.56%
controls:4.66%
cases:5.56%
controls:1.06%
—
—
cases:5.66%
controls:0.93%
cases:19.23%
controls:4.41%
cases:20.00%
controls:7.71%
14
82
148
1527
9
75
153
1534
9
17
153
1592
—
9
15
150
1592
25
69
105
1494
18
105
72
1256
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
26474-7 [3019198]
1.0e-01
4.5e-01
2.0e+00
—
2.1e+00
1.2e+00
9.3e-01
cases:9.88%
controls:9.01%
cases:9.88%
controls:6.53%
cases:9.88%
controls:1.43%
—
—
cases:10.06%
controls:1.37%
cases:21.54%
controls:7.29%
cases:28.89%
controls:13.81%
16
145
146
1464
16
105
146
1504
16
23
146
1586
—
16
22
143
1585
28
114
102
1449
26
188
64
1173
Eosinophils [#/volume] in Blood
26449-9 [3013115]
26449-9 [3013115]
7.9e-02
4.4e-01
2.0e+00
—
2.0e+00
1.2e+00
9.9e-01
cases:9.88%
controls:9.20%
cases:9.88%
controls:6.59%
cases:10.49%
controls:1.49%
—
—
cases:10.06%
controls:1.43%
cases:20.77%
controls:7.36%
cases:30.00%
controls:13.74%
16
148
146
1461
16
106
146
1503
17
24
145
1585
—
16
23
143
1584
27
115
103
1448
27
187
63
1174
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
A03FA01 [21600484]
5.8e-01
—
—
—
—
4.2e+00
1.9e+00
cases:3.70%
controls:2.11%
—
—
—
—
—
—
—
—
cases:26.15%
controls:0.51%
cases:6.67%
controls:1.03%
6
34
156
1575
—
—
—
—
34
8
96
1555
6
14
84
1347
One hour or less
ZXE00 [2001311394]
ZXE00 [2001311394]
7.8e-01
1.2e+00
—
1.0e+50
2.3e+00
2.2e+00
1.6e+00
cases:12.35%
controls:6.09%
cases:5.56%
controls:1.68%
—
—
cases:4.94%
controls:0.00%
cases:3.14%
controls:0.31%
cases:8.46%
controls:1.02%
cases:15.56%
controls:3.53%
20
98
142
1511
9
27
153
1582
—
8
0
154
1609
5
5
154
1602
11
16
119
1547
14
48
76
1313
Emergency Room Visit
ER [9203]
ER [9203]
1.4e-01
8.7e-01
2.1e+00
1.0e+50
1.8e+00
1.3e+00
2.6e-01
cases:33.33%
controls:30.39%
cases:22.84%
controls:11.06%
cases:14.81%
controls:1.99%
cases:9.88%
controls:0.00%
cases:7.55%
controls:1.31%
cases:31.54%
controls:11.13%
cases:33.33%
controls:27.92%
54
489
108
1120
37
178
125
1431
24
32
138
1577
16
0
146
1609
12
21
147
1586
41
174
89
1389
30
380
60
981
Oral Surgery
19 [38004464]
19 [38004464]
2.2e+00
—
—
1.0e+50
—
—
3.6e+00
cases:4.32%
controls:0.50%
—
—
—
—
cases:3.70%
controls:0.00%
—
—
—
—
cases:14.44%
controls:0.44%
7
8
155
1601
—
—
6
0
156
1609
—
—
13
6
77
1355
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
28540-3 [3003338]
-1.2e-02
4.1e-02
1.3e+00
2.7e+00
1.8e+00
5.9e-01
2.0e-01
cases:24.69%
controls:24.92%
cases:20.99%
controls:20.32%
cases:14.20%
controls:4.29%
cases:4.32%
controls:0.31%
cases:20.13%
controls:4.04%
cases:33.08%
controls:21.56%
cases:40.00%
controls:35.27%
40
401
122
1208
34
327
128
1282
23
69
139
1540
7
5
155
1604
32
65
127
1542
43
337
87
1226
36
480
54
881
Immunohistochemistry procedure
117617002 [4035726]
117617002 [4035726]
2.8e+00
—
—
1.0e+50
—
—
2.8e+00
cases:4.94%
controls:0.31%
—
—
—
—
cases:9.88%
controls:0.00%
—
—
—
—
cases:6.67%
controls:0.44%
8
5
154
1604
—
—
16
0
146
1609
—
—
6
6
84
1355
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1988-5 [3020460]
1.1e-01
3.7e-01
1.8e+00
—
2.5e+00
1.2e+00
5.5e-01
cases:27.16%
controls:25.05%
cases:23.46%
controls:17.40%
cases:17.28%
controls:3.36%
—
—
cases:28.30%
controls:3.05%
cases:43.08%
controls:18.68%
cases:47.78%
controls:34.61%
44
403
118
1206
38
280
124
1329
28
54
134
1555
—
45
49
114
1558
56
292
74
1271
43
471
47
890
Loss of teeth due to accident, extraction or local periodontal disease
K08.1 [45591573]
K08.1 [45591573]
—
-1.0e+50
—
—
—
2.9e+00
2.6e+00
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
cases:10.77%
controls:0.64%
cases:18.89%
controls:1.76%
—
0
10
162
1599
—
—
—
14
10
116
1553
17
24
73
1337
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
19072-8 [3016431]
6.1e-01
8.1e-01
—
—
3.5e+00
2.0e+00
8.3e-01
cases:12.96%
controls:7.52%
cases:11.11%
controls:5.28%
—
—
—
—
cases:14.47%
controls:0.50%
cases:25.38%
controls:4.61%
cases:24.44%
controls:12.42%
21
121
141
1488
18
85
144
1524
—
—
23
8
136
1599
33
72
97
1491
22
169
68
1192
dexamethasone and antiinfectives
S02CA06 [21605178]
S02CA06 [21605178]
—
—
—
—
—
3.2e+00
2.3e+00
—
—
—
—
—
—
—
—
—
—
cases:8.46%
controls:0.38%
cases:5.56%
controls:0.59%
—
—
—
—
—
11
6
119
1557
5
8
85
1353
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
1995-0 [3021347]
5.9e-01
7.3e-01
—
—
3.6e+00
1.8e+00
5.2e-01
cases:11.73%
controls:6.84%
cases:9.88%
controls:5.03%
—
—
—
—
cases:12.58%
controls:0.37%
cases:20.00%
controls:3.97%
cases:16.67%
controls:10.65%
19
110
143
1499
16
81
146
1528
—
—
20
6
139
1601
26
62
104
1501
15
145
75
1216
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
62238-1 [40764999]
2.4e-01
5.0e-01
2.1e+00
—
2.2e+00
1.1e+00
1.7e-01
cases:23.46%
controls:19.39%
cases:27.16%
controls:18.40%
cases:21.60%
controls:3.29%
—
—
cases:25.16%
controls:3.61%
cases:40.77%
controls:18.94%
cases:38.89%
controls:34.83%
38
312
124
1297
44
296
118
1313
35
53
127
1556
—
40
58
119
1549
53
296
77
1267
35
474
55
887
Inpatient Visit
IP [9201]
IP [9201]
4.8e-01
9.3e-01
2.3e+00
1.0e+50
—
2.0e+00
9.5e-01
cases:11.73%
controls:7.58%
cases:7.41%
controls:3.05%
cases:4.94%
controls:0.50%
cases:12.35%
controls:0.00%
—
—
cases:23.08%
controls:3.84%
cases:22.22%
controls:9.99%
19
122
143
1487
12
49
150
1560
8
8
154
1601
20
0
142
1609
—
30
60
100
1503
20
136
70
1225
ibuprofen
R02AX02 [1588667]
R02AX02 [1588667]
3.7e-01
4.3e-01
1.7e+00
1.0e+50
2.2e+00
1.3e+00
5.7e-01
cases:34.57%
controls:26.72%
cases:16.67%
controls:11.50%
cases:8.02%
controls:1.49%
cases:3.09%
controls:0.00%
cases:13.21%
controls:1.62%
cases:33.08%
controls:11.64%
cases:37.78%
controls:25.64%
56
430
106
1179
27
185
135
1424
13
24
149
1585
5
0
157
1609
21
26
138
1581
43
182
87
1381
34
349
56
1012
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
M01AE01 [21603967]
3.7e-01
4.3e-01
1.7e+00
1.0e+50
2.2e+00
1.3e+00
5.7e-01
cases:34.57%
controls:26.72%
cases:16.67%
controls:11.50%
cases:8.02%
controls:1.49%
cases:3.09%
controls:0.00%
cases:13.21%
controls:1.62%
cases:33.08%
controls:11.64%
cases:37.78%
controls:25.64%
56
430
106
1179
27
185
135
1424
13
24
149
1585
5
0
157
1609
21
26
138
1581
43
182
87
1381
34
349
56
1012
dexamethasone and antiinfectives
S03CA01 [21605206]
S03CA01 [21605206]
8.9e-01
—
—
—
—
3.1e+00
2.0e+00
cases:3.70%
controls:1.55%
—
—
—
—
—
—
—
—
cases:12.31%
controls:0.64%
cases:13.33%
controls:1.98%
6
25
156
1584
—
—
—
—
16
10
114
1553
12
27
78
1334
Normoblasts [#/volume] in Blood
715-3 [3021589]
715-3 [3021589]
1.3e-01
4.8e-01
2.0e+00
—
2.0e+00
9.9e-01
-7.1e-02
cases:8.02%
controls:7.15%
cases:11.11%
controls:7.21%
cases:11.73%
controls:1.68%
—
—
cases:10.06%
controls:1.56%
cases:18.46%
controls:7.74%
cases:13.33%
controls:14.18%
13
115
149
1494
18
116
144
1493
19
27
143
1582
—
16
25
143
1582
24
121
106
1442
12
193
78
1168
Extended examination of mouth
SAA03 [2001310276]
SAA03 [2001310276]
7.5e-01
1.3e+00
—
—
—
3.0e+00
1.9e+00
cases:11.73%
controls:5.90%
cases:4.94%
controls:1.43%
—
—
—
—
—
—
cases:19.23%
controls:1.15%
cases:21.11%
controls:3.67%
19
95
143
1514
8
23
154
1586
—
—
—
25
18
105
1545
19
50
71
1311
Case Management Agency
251B00000X [38004193]
251B00000X [38004193]
-1.2e-01
1.1e-01
8.6e-01
2.8e+00
1.2e+00
5.8e-01
-8.0e-02
cases:56.17%
controls:59.17%
cases:52.47%
controls:49.84%
cases:35.80%
controls:19.02%
cases:19.14%
controls:1.37%
cases:44.65%
controls:19.29%
cases:64.62%
controls:50.48%
cases:67.78%
controls:69.51%
91
952
71
657
85
802
77
807
58
306
104
1303
31
22
131
1587
71
310
88
1297
84
789
46
774
61
946
29
415
oxycodone; oral, parenteral
N02AA05 [21604260]
N02AA05 [21604260]
—
1.6e+00
—
—
—
3.4e+00
1.5e+00
—
—
cases:3.09%
controls:0.62%
—
—
—
—
—
—
cases:23.08%
controls:1.02%
cases:10.00%
controls:2.35%
—
5
10
157
1599
—
—
—
30
16
100
1547
9
32
81
1329
General anesthesia, balanced
WX408 [2001310808]
WX408 [2001310808]
7.6e-01
—
—
—
1.0e+50
3.0e+00
1.8e+00
cases:6.17%
controls:2.98%
—
—
—
—
—
—
cases:5.66%
controls:0.00%
cases:8.46%
controls:0.45%
cases:7.78%
controls:1.32%
10
48
152
1561
—
—
—
9
0
150
1607
11
7
119
1556
7
18
83
1343
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
14804-9 [3022250]
—
1.6e+00
—
—
—
2.6e+00
2.2e+00
—
—
cases:4.94%
controls:1.06%
—
—
—
—
—
—
cases:8.46%
controls:0.70%
cases:14.44%
controls:1.76%
—
8
17
154
1592
—
—
—
11
11
119
1552
13
24
77
1337
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2951-2 [3019550]
1.3e-01
3.2e-01
1.7e+00
—
2.3e+00
8.3e-01
1.6e-01
cases:30.86%
controls:28.09%
cases:30.25%
controls:23.87%
cases:20.37%
controls:4.66%
—
—
cases:30.19%
controls:4.17%
cases:43.85%
controls:25.40%
cases:46.67%
controls:42.62%
50
452
112
1157
49
384
113
1225
33
75
129
1534
—
48
67
111
1540
57
397
73
1166
42
580
48
781
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
2601-3 [3012095]
9.7e-01
1.0e+00
—
—
—
3.3e+00
1.5e+00
cases:6.17%
controls:2.42%
cases:3.70%
controls:1.37%
—
—
—
—
—
—
cases:23.85%
controls:1.15%
cases:11.11%
controls:2.79%
10
39
152
1570
6
22
156
1587
—
—
—
31
18
99
1545
10
38
80
1323
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
77397-8 [46236098]
5.5e-01
—
—
—
—
3.1e+00
1.5e+00
cases:4.94%
controls:2.92%
—
—
—
—
—
—
—
—
cases:16.15%
controls:0.83%
cases:14.44%
controls:3.45%
8
47
154
1562
—
—
—
—
21
13
109
1550
13
47
77
1314
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2823-3 [3023103]
1.2e-01
2.9e-01
1.6e+00
—
2.2e+00
8.1e-01
1.6e-01
cases:30.86%
controls:28.28%
cases:29.63%
controls:23.99%
cases:20.37%
controls:4.85%
—
—
cases:30.19%
controls:4.48%
cases:43.85%
controls:25.85%
cases:46.67%
controls:42.62%
50
455
112
1154
48
386
114
1223
33
78
129
1531
—
48
72
111
1535
57
404
73
1159
42
580
48
781
Dry eye syndrome
H04.10 [2000502254]
H04.10 [2000502254]
—
—
—
—
—
2.8e+00
1.7e+00
—
—
—
—
—
—
—
—
—
—
cases:6.15%
controls:0.38%
cases:11.11%
controls:2.13%
—
—
—
—
—
8
6
122
1557
10
29
80
1332
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
620-5 [3007853]
—
1.2e+00
—
—
—
3.0e+00
1.5e+00
—
—
cases:3.09%
controls:0.99%
—
—
—
—
—
—
cases:14.62%
controls:0.83%
cases:10.00%
controls:2.35%
—
5
16
157
1593
—
—
—
19
13
111
1550
9
32
81
1329
Bacteria identified in Isolate by Culture
43409-2 [3042936]
43409-2 [3042936]
8.3e-01
1.2e+00
—
—
—
2.7e+00
1.8e+00
cases:4.32%
controls:1.93%
cases:3.09%
controls:0.93%
—
—
—
—
—
—
cases:10.77%
controls:0.83%
cases:15.56%
controls:2.87%
7
31
155
1578
5
15
157
1594
—
—
—
14
13
116
1550
14
39
76
1322
pH of Serum or Plasma
2753-2 [3018418]
2753-2 [3018418]
6.3e-01
8.3e-01
—
—
2.9e+00
1.6e+00
6.0e-01
cases:8.64%
controls:4.79%
cases:7.41%
controls:3.36%
—
—
—
—
cases:6.29%
controls:0.37%
cases:13.08%
controls:2.94%
cases:12.22%
controls:7.13%
14
77
148
1532
12
54
150
1555
—
—
10
6
149
1601
17
46
113
1517
11
97
79
1264
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
2324-2 [3026910]
1.5e-01
-6.4e-02
1.8e+00
—
2.7e+00
3.1e-01
1.6e-01
cases:15.43%
controls:13.61%
cases:6.79%
controls:7.21%
cases:4.32%
controls:0.75%
—
—
cases:4.40%
controls:0.31%
cases:8.46%
controls:6.33%
cases:17.78%
controls:15.50%
25
219
137
1390
11
116
151
1493
7
12
155
1597
—
7
5
152
1602
11
99
119
1464
16
211
74
1150
dexamethasone
C05AA09 [21601613]
C05AA09 [21601613]
—
—
—
—
—
2.7e+00
1.7e+00
—
—
—
—
—
—
—
—
—
—
cases:4.62%
controls:0.32%
cases:8.89%
controls:1.69%
—
—
—
—
—
6
5
124
1558
8
23
82
1338
dexamethasone
D10AA03 [21602286]
D10AA03 [21602286]
—
—
—
—
—
2.7e+00
1.7e+00
—
—
—
—
—
—
—
—
—
—
cases:4.62%
controls:0.32%
cases:8.89%
controls:1.69%
—
—
—
—
—
6
5
124
1558
8
23
82
1338
dexamethasone
S02BA06 [21605168]
S02BA06 [21605168]
—
—
—
—
—
2.7e+00
1.7e+00
—
—
—
—
—
—
—
—
—
—
cases:4.62%
controls:0.32%
cases:8.89%
controls:1.69%
—
—
—
—
—
6
5
124
1558
8
23
82
1338
dexamethasone
D07AB19 [21602116]
D07AB19 [21602116]
—
—
—
—
—
2.7e+00
1.7e+00
—
—
—
—
—
—
—
—
—
—
cases:4.62%
controls:0.32%
cases:8.89%
controls:1.69%
—
—
—
—
—
6
5
124
1558
8
23
82
1338
codeine and paracetamol
N02AJ06 [1123647]
N02AJ06 [1123647]
6.0e-02
7.9e-01
1.3e+00
—
2.5e+00
1.9e+00
7.5e-01
cases:11.73%
controls:11.12%
cases:8.64%
controls:4.10%
cases:3.70%
controls:1.06%
—
—
cases:8.81%
controls:0.75%
cases:20.00%
controls:3.65%
cases:20.00%
controls:10.58%
19
179
143
1430
14
66
148
1543
6
17
156
1592
—
14
12
145
1595
26
57
104
1506
18
144
72
1217
12 lead EKG panel
34534-8 [3044889]
34534-8 [3044889]
2.8e-01
3.2e-01
2.0e+00
—
2.4e+00
8.1e-01
-7.6e-02
cases:20.37%
controls:16.22%
cases:12.35%
controls:9.26%
cases:6.17%
controls:0.87%
—
—
cases:11.95%
controls:1.24%
cases:17.69%
controls:8.70%
cases:21.11%
controls:22.41%
33
261
129
1348
20
149
142
1460
10
14
152
1595
—
19
20
140
1587
23
136
107
1427
19
305
71
1056
Internal Medicine
11 [38004456]
11 [38004456]
2.5e-01
7.1e-01
1.6e+00
—
1.6e+00
1.1e+00
2.6e-01
cases:29.01%
controls:24.11%
cases:19.75%
controls:10.75%
cases:9.88%
controls:2.18%
—
—
cases:6.92%
controls:1.43%
cases:24.62%
controls:9.47%
cases:25.56%
controls:20.94%
47
388
115
1221
32
173
130
1436
16
35
146
1574
—
11
23
148
1584
32
148
98
1415
23
285
67
1076
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
34531-4 [3044640]
7.9e-01
7.9e-01
—
—
—
2.9e+00
1.4e+00
cases:8.02%
controls:3.79%
cases:5.56%
controls:2.61%
—
—
—
—
—
—
cases:19.23%
controls:1.34%
cases:16.67%
controls:4.56%
13
61
149
1548
9
42
153
1567
—
—
—
25
21
105
1542
15
62
75
1299
Panorama tomography of teeth and jaws or similar X-ray examination
EB1HA [2001301913]
EB1HA [2001301913]
5.9e-01
7.7e-01
—
—
—
3.0e+00
1.1e+00
cases:10.49%
controls:6.09%
cases:3.70%
controls:1.74%
—
—
—
—
—
—
cases:13.85%
controls:0.77%
cases:14.44%
controls:5.36%
17
98
145
1511
6
28
156
1581
—
—
—
18
12
112
1551
13
73
77
1288
Oncology Clinic/Center
261QX0200X [38004268]
261QX0200X [38004268]
4.1e+00
1.0e+50
1.0e+50
1.0e+50
1.0e+50
—
—
cases:20.99%
controls:0.44%
cases:9.26%
controls:0.00%
cases:11.73%
controls:0.00%
cases:50.62%
controls:0.00%
cases:5.66%
controls:0.00%
—
—
—
—
34
7
128
1602
15
0
147
1609
19
0
143
1609
82
0
80
1609
9
0
150
1607
—
—
nystatin; oral
A07AA02 [21600604]
A07AA02 [21600604]
1.9e+00
—
—
—
—
4.1e+00
1.9e+00
cases:3.70%
controls:0.56%
—
—
—
—
—
—
—
—
cases:16.15%
controls:0.32%
cases:5.56%
controls:0.88%
6
9
156
1600
—
—
—
—
21
5
109
1558
5
12
85
1349
Short blood count panel - Blood
55429-5 [40758558]
55429-5 [40758558]
4.7e-02
3.9e-01
1.6e+00
—
2.6e+00
1.5e+00
8.8e-01
cases:4.94%
controls:4.72%
cases:3.70%
controls:2.55%
cases:3.09%
controls:0.62%
—
—
cases:5.66%
controls:0.44%
cases:9.23%
controls:2.30%
cases:14.44%
controls:6.54%
8
76
154
1533
6
41
156
1568
5
10
157
1599
—
9
7
150
1600
12
36
118
1527
13
89
77
1272
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1742-6 [3006923]
1.1e-01
2.6e-01
1.2e+00
—
2.1e+00
8.2e-01
2.0e-01
cases:31.48%
controls:29.15%
cases:27.16%
controls:22.31%
cases:11.73%
controls:3.92%
—
—
cases:22.01%
controls:3.48%
cases:42.31%
controls:24.38%
cases:47.78%
controls:42.91%
51
469
111
1140
44
359
118
1250
19
63
143
1546
—
35
56
124
1551
55
381
75
1182
43
584
47
777
CBC panel - Blood by Automated count
58410-2 [40761511]
58410-2 [40761511]
8.2e-02
1.4e-01
1.5e+00
—
1.7e+00
8.5e-01
1.0e-01
cases:29.01%
controls:27.35%
cases:22.84%
controls:20.45%
cases:16.05%
controls:4.23%
—
—
cases:18.24%
controls:3.80%
cases:39.23%
controls:21.56%
cases:38.89%
controls:36.52%
47
440
115
1169
37
329
125
1280
26
68
136
1541
—
29
61
130
1546
51
337
79
1226
35
497
55
864
dexamethasone; local oral
A01AC02 [21600035]
A01AC02 [21600035]
—
—
—
—
—
2.4e+00
1.6e+00
—
—
—
—
—
—
—
—
—
—
cases:4.62%
controls:0.45%
cases:8.89%
controls:1.84%
—
—
—
—
—
6
7
124
1556
8
25
82
1336
doxycycline; oral, parenteral
J01AA02 [21602800]
J01AA02 [21602800]
3.9e-01
1.3e+00
2.7e+00
—
—
7.8e-01
7.4e-01
cases:23.46%
controls:17.15%
cases:14.81%
controls:4.41%
cases:4.32%
controls:0.31%
—
—
—
—
cases:10.77%
controls:5.25%
cases:25.56%
controls:14.11%
38
276
124
1333
24
71
138
1538
7
5
155
1604
—
—
14
82
116
1481
23
192
67
1169
General anaesthesia
WX402 [2001310806]
WX402 [2001310806]
1.5e+00
1.6e+00
—
1.0e+50
—
2.4e+00
1.6e+00
cases:4.94%
controls:1.18%
cases:4.32%
controls:0.93%
—
—
cases:3.09%
controls:0.00%
—
—
cases:8.46%
controls:0.83%
cases:11.11%
controls:2.57%
8
19
154
1590
7
15
155
1594
—
5
0
157
1609
—
11
13
119
1550
10
35
80
1326
chloramphenicol
S01AA01 [21603554]
S01AA01 [21603554]
5.5e-01
9.4e-01
—
—
—
2.8e+00
1.2e+00
cases:11.11%
controls:6.71%
cases:4.32%
controls:1.74%
—
—
—
—
—
—
cases:22.31%
controls:1.79%
cases:25.56%
controls:9.40%
18
108
144
1501
7
28
155
1581
—
—
—
29
28
101
1535
23
128
67
1233
chloramphenicol
S03AA08 [21605197]
S03AA08 [21605197]
5.5e-01
9.4e-01
—
—
—
2.8e+00
1.2e+00
cases:11.11%
controls:6.71%
cases:4.32%
controls:1.74%
—
—
—
—
—
—
cases:22.31%
controls:1.79%
cases:25.56%
controls:9.40%
18
108
144
1501
7
28
155
1581
—
—
—
29
28
101
1535
23
128
67
1233
General Practice
1 [38004446]
1 [38004446]
1.6e-01
1.5e-01
1.7e+00
1.0e+50
2.2e+00
7.9e-01
3.3e-01
cases:14.81%
controls:12.93%
cases:8.02%
controls:6.96%
cases:4.94%
controls:0.93%
cases:5.56%
controls:0.00%
cases:8.81%
controls:1.06%
cases:13.85%
controls:6.78%
cases:23.33%
controls:17.93%
24
208
138
1401
13
112
149
1497
8
15
154
1594
9
0
153
1609
14
17
145
1590
18
106
112
1457
21
244
69
1117
dexamethasone and antiinfectives
S01CA01 [21603652]
S01CA01 [21603652]
—
—
—
—
—
2.2e+00
1.6e+00
—
—
—
—
—
—
—
—
—
—
cases:4.62%
controls:0.51%
cases:8.89%
controls:1.84%
—
—
—
—
—
6
8
124
1555
8
25
82
1336
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1751-7 [3024561]
5.7e-01
8.4e-01
2.3e+00
—
—
1.6e+00
4.8e-01
cases:12.96%
controls:7.77%
cases:9.88%
controls:4.54%
cases:6.17%
controls:0.68%
—
—
—
—
cases:20.77%
controls:4.93%
cases:16.67%
controls:11.02%
21
125
141
1484
16
73
146
1536
10
11
152
1598
—
—
27
77
103
1486
15
150
75
1211
Scheduled procedure
ZXD10 [2001311387]
ZXD10 [2001311387]
7.9e-01
9.4e-01
—
1.0e+50
—
2.3e+00
1.5e+00
cases:12.35%
controls:6.03%
cases:4.32%
controls:1.74%
—
—
cases:3.09%
controls:0.00%
—
—
cases:12.31%
controls:1.41%
cases:14.44%
controls:3.53%
20
97
142
1512
7
28
155
1581
—
5
0
157
1609
—
16
22
114
1541
13
48
77
1313
INR in Blood by Coagulation assay
34714-6 [3032080]
34714-6 [3032080]
2.3e-01
4.4e-01
1.3e+00
—
2.2e+00
1.5e+00
6.5e-01
cases:11.73%
controls:9.57%
cases:9.26%
controls:6.15%
cases:6.17%
controls:1.68%
—
—
cases:10.06%
controls:1.18%
cases:20.77%
controls:5.44%
cases:21.11%
controls:12.27%
19
154
143
1455
15
99
147
1510
10
27
152
1582
—
16
19
143
1588
27
85
103
1478
19
167
71
1194
clindamycin; oral, parenteral
J01FF01 [21602985]
J01FF01 [21602985]
—
—
—
—
—
2.2e+00
1.5e+00
—
—
—
—
—
—
—
—
—
—
cases:9.23%
controls:1.09%
cases:10.00%
controls:2.35%
—
—
—
—
—
12
17
118
1546
9
32
81
1329
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
N02AX02 [21604298]
-8.0e-02
8.0e-01
-1.0e+50
—
2.3e+00
1.5e+00
1.7e-01
cases:6.17%
controls:6.65%
cases:6.79%
controls:3.17%
cases:0.00%
controls:0.56%
—
—
cases:6.29%
controls:0.68%
cases:13.85%
controls:3.58%
cases:7.78%
controls:6.61%
10
107
152
1502
11
51
151
1558
0
9
162
1600
—
10
11
149
1596
18
56
112
1507
7
90
83
1271
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
J01MA12 [21603019]
1.4e+00
—
—
—
—
2.3e+00
8.9e-01
cases:8.02%
controls:2.18%
—
—
—
—
—
—
—
—
cases:9.23%
controls:0.96%
cases:5.56%
controls:2.35%
13
35
149
1574
—
—
—
—
12
15
118
1548
5
32
85
1329
Teaching
WZC30 [2001310891]
WZC30 [2001310891]
1.6e+00
—
1.0e+50
—
—
3.7e+00
—
cases:4.32%
controls:0.93%
—
—
cases:3.09%
controls:0.00%
—
—
—
—
cases:13.08%
controls:0.38%
—
—
7
15
155
1594
—
5
0
157
1609
—
—
17
6
113
1557
—
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
4537-7 [3013707]
1.9e-01
5.0e-02
1.6e+00
—
2.1e+00
6.4e-01
4.0e-01
cases:17.90%
controls:15.29%
cases:11.11%
controls:10.63%
cases:6.17%
controls:1.37%
—
—
cases:6.92%
controls:0.93%
cases:16.15%
controls:9.21%
cases:27.78%
controls:20.50%
29
246
133
1363
18
171
144
1438
10
22
152
1587
—
11
15
148
1592
21
144
109
1419
25
279
65
1082
Examination of eyes and vision
Z01.0 [45566391]
Z01.0 [45566391]
—
—
—
—
—
2.1e+00
1.4e+00
—
—
—
—
—
—
—
—
—
—
cases:6.92%
controls:0.90%
cases:11.11%
controls:2.87%
—
—
—
—
—
9
14
121
1549
10
39
80
1322
More than one and less than three hours
ZXE10 [2001311401]
ZXE10 [2001311401]
4.0e-01
—
—
—
—
1.9e+00
1.6e+00
cases:8.02%
controls:5.53%
—
—
—
—
—
—
—
—
cases:6.92%
controls:1.09%
cases:13.33%
controls:2.94%
13
89
149
1520
—
—
—
—
9
17
121
1546
12
40
78
1321
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
14979-9 [3018677]
4.1e-01
—
—
—
1.0e+50
2.1e+00
1.3e+00
cases:3.70%
controls:2.49%
—
—
—
—
—
—
cases:3.14%
controls:0.00%
cases:4.62%
controls:0.58%
cases:12.22%
controls:3.53%
6
40
156
1569
—
—
—
5
0
154
1607
6
9
124
1554
11
48
79
1313
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
14920-3 [3008486]
2.9e-01
4.7e-01
1.8e+00
—
1.7e+00
7.1e-01
2.3e-02
cases:20.37%
controls:16.03%
cases:13.58%
controls:8.95%
cases:4.32%
controls:0.75%
—
—
cases:5.03%
controls:1.00%
cases:16.92%
controls:9.09%
cases:23.33%
controls:22.92%
33
258
129
1351
22
144
140
1465
7
12
155
1597
—
8
16
151
1591
22
142
108
1421
21
312
69
1049
antibiotics in combination with corticosteroids
D01AA20 [21601918]
D01AA20 [21601918]
1.2e+00
—
—
—
—
3.5e+00
1.7e+00
cases:3.70%
controls:1.12%
—
—
—
—
—
—
—
—
cases:9.23%
controls:0.32%
cases:5.56%
controls:1.03%
6
18
156
1591
—
—
—
—
12
5
118
1558
5
14
85
1347
General Practice Dentistry
1223G0001X [38003675]
1223G0001X [38003675]
—
—
—
—
1.0e+50
—
3.4e+00
—
—
—
—
—
—
—
—
cases:3.14%
controls:0.00%
—
—
cases:10.00%
controls:0.37%
—
—
—
—
5
0
154
1607
—
9
5
81
1356
Flexible laryngoscopy
UDQ12 [2001301827]
UDQ12 [2001301827]
—
—
—
—
—
—
3.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.89%
controls:0.37%
—
—
—
—
—
—
8
5
82
1356
amoxicillin; oral, parenteral
J01CA04 [21602823]
J01CA04 [21602823]
4.8e-01
1.3e+00
1.8e+00
—
—
9.6e-01
9.6e-01
cases:27.16%
controls:18.77%
cases:17.28%
controls:5.28%
cases:3.70%
controls:0.62%
—
—
—
—
cases:13.85%
controls:5.82%
cases:35.56%
controls:17.49%
44
302
118
1307
28
85
134
1524
6
10
156
1599
—
—
18
91
112
1472
32
238
58
1123
Dental impressions
SBB10 [2001310299]
SBB10 [2001310299]
-1.0e+50
—
—
—
—
—
3.2e+00
cases:0.00%
controls:0.44%
—
—
—
—
—
—
—
—
—
—
cases:10.00%
controls:0.44%
0
7
162
1602
—
—
—
—
—
9
6
81
1355
Bacterial infection, unspecified
A49.9 [45590816]
A49.9 [45590816]
—
—
—
—
—
3.2e+00
1.2e+00
—
—
—
—
—
—
—
—
—
—
cases:12.31%
controls:0.58%
cases:5.56%
controls:1.69%
—
—
—
—
—
16
9
114
1554
5
23
85
1338
Hematology
82 [38004501]
82 [38004501]
—
—
—
—
—
3.1e+00
2.1e+00
—
—
—
—
—
—
—
—
—
—
cases:6.92%
controls:0.32%
cases:5.56%
controls:0.73%
—
—
—
—
—
9
5
121
1558
5
10
85
1351
Extensive body CT
JN4BD [2001310899]
JN4BD [2001310899]
—
—
—
—
—
—
3.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.78%
controls:0.37%
—
—
—
—
—
—
7
5
83
1356
Promyelocytes/Leukocytes in Blood
26524-9 [3021440]
26524-9 [3021440]
—
2.0e+00
—
—
—
3.1e+00
1.1e+00
—
—
cases:3.09%
controls:0.44%
—
—
—
—
—
—
cases:14.62%
controls:0.77%
cases:6.67%
controls:2.35%
—
5
7
157
1602
—
—
—
19
12
111
1551
6
32
84
1329
Sedation and analgesia
WX002 [2001310758]
WX002 [2001310758]
5.7e-02
—
—
—
—
3.0e+00
1.5e+00
cases:3.09%
controls:2.92%
—
—
—
—
—
—
—
—
cases:8.46%
controls:0.45%
cases:6.67%
controls:1.62%
5
47
157
1562
—
—
—
—
11
7
119
1556
6
22
84
1339
mometasone; nasal
R01AD09 [21605051]
R01AD09 [21605051]
3.3e-01
1.6e+00
—
—
—
1.4e+00
7.1e-01
cases:9.88%
controls:7.27%
cases:13.58%
controls:3.05%
—
—
—
—
—
—
cases:10.77%
controls:2.88%
cases:12.22%
controls:6.39%
16
117
146
1492
22
49
140
1560
—
—
—
14
45
116
1518
11
87
79
1274
Myelocytes/Leukocytes in Blood
26498-6 [3017181]
26498-6 [3017181]
—
2.0e+00
—
—
—
3.0e+00
1.1e+00
—
—
cases:3.09%
controls:0.44%
—
—
—
—
—
—
cases:14.62%
controls:0.83%
cases:6.67%
controls:2.42%
—
5
7
157
1602
—
—
—
19
13
111
1550
6
33
84
1328
Metamyelocytes/Leukocytes in Blood
28541-1 [3002179]
28541-1 [3002179]
—
—
—
—
—
3.0e+00
1.1e+00
—
—
—
—
—
—
—
—
—
—
cases:12.31%
controls:0.70%
cases:6.67%
controls:2.28%
—
—
—
—
—
16
11
114
1552
6
31
84
1330
Changing form of teeth in prepation for prosthodontic work
SPA00 [2001310458]
SPA00 [2001310458]
—
—
—
—
—
—
3.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.67%
controls:0.37%
—
—
—
—
—
—
6
5
84
1356
Pharmacy visit
OMOP4822462 [581458]
OMOP4822462 [581458]
1.4e-01
5.9e-01
6.5e-01
1.4e+00
8.5e-01
7.4e-01
1.4e-01
cases:88.89%
controls:87.38%
cases:88.27%
controls:80.73%
cases:66.05%
controls:50.34%
cases:7.41%
controls:1.86%
cases:67.30%
controls:46.86%
cases:90.77%
controls:82.47%
cases:93.33%
controls:92.43%
144
1406
18
203
143
1299
19
310
107
810
55
799
12
30
150
1579
107
753
52
854
118
1289
12
274
84
1258
6
103
Cathetrisation of artery
TPH07 [2001309747]
TPH07 [2001309747]
1.6e+00
—
—
—
—
2.9e+00
—
cases:4.32%
controls:0.87%
—
—
—
—
—
—
—
—
cases:5.38%
controls:0.32%
—
—
7
14
155
1595
—
—
—
—
7
5
123
1558
—
antibiotics in combination with other drugs
S01AA20 [21603571]
S01AA20 [21603571]
4.3e-01
8.5e-01
—
—
—
1.8e+00
1.0e+00
cases:10.49%
controls:7.09%
cases:4.94%
controls:2.18%
—
—
—
—
—
—
cases:12.31%
controls:2.24%
cases:20.00%
controls:8.45%
17
114
145
1495
8
35
154
1574
—
—
—
16
35
114
1528
18
115
72
1246
Blasts/Leukocytes in Blood
26446-5 [3025159]
26446-5 [3025159]
—
2.0e+00
—
—
—
2.7e+00
—
—
—
cases:3.09%
controls:0.44%
—
—
—
—
—
—
cases:10.77%
controls:0.77%
—
—
—
5
7
157
1602
—
—
—
14
12
116
1551
—
Carbon dioxide [Partial pressure] in Capillary blood
2020-6 [3023024]
2020-6 [3023024]
—
-1.0e+50
—
—
—
2.7e+00
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
cases:4.62%
controls:0.32%
—
—
—
0
10
162
1599
—
—
—
6
5
124
1558
—
pH of Capillary blood
2745-8 [3009343]
2745-8 [3009343]
—
-1.0e+50
—
—
—
2.7e+00
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
cases:4.62%
controls:0.32%
—
—
—
0
10
162
1599
—
—
—
6
5
124
1558
—
benzathine phenoxymethylpenicillin; oral
J01CE10 [21602850]
J01CE10 [21602850]
6.6e-01
9.7e-01
—
—
2.7e+00
1.0e+00
3.8e-01
cases:15.43%
controls:8.64%
cases:6.17%
controls:2.42%
—
—
—
—
cases:4.40%
controls:0.31%
cases:7.69%
controls:2.94%
cases:13.33%
controls:9.48%
25
139
137
1470
10
39
152
1570
—
—
7
5
152
1602
10
46
120
1517
12
129
78
1232
phenoxymethylpenicillin; oral
J01CE02 [21602842]
J01CE02 [21602842]
6.6e-01
9.7e-01
—
—
2.7e+00
1.0e+00
3.8e-01
cases:15.43%
controls:8.64%
cases:6.17%
controls:2.42%
—
—
—
—
cases:4.40%
controls:0.31%
cases:7.69%
controls:2.94%
cases:13.33%
controls:9.48%
25
139
137
1470
10
39
152
1570
—
—
7
5
152
1602
10
46
120
1517
12
129
78
1232
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
GD1UA [2001303652]
1.0e+00
—
—
—
1.0e+50
2.7e+00
1.3e+00
cases:4.94%
controls:1.86%
—
—
—
—
—
—
cases:6.29%
controls:0.00%
cases:8.46%
controls:0.64%
cases:7.78%
controls:2.28%
8
30
154
1579
—
—
—
10
0
149
1607
11
10
119
1553
7
31
83
1330
lorazepam; oral, parenteral, sublingual
N05BA06 [21604571]
N05BA06 [21604571]
—
—
-1.0e+50
—
—
2.6e+00
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
cases:7.69%
controls:0.64%
—
—
—
—
0
5
162
1604
—
—
10
10
120
1553
—
Intravenous
ZX120 [2001311495]
ZX120 [2001311495]
-1.0e+50
—
—
—
—
2.5e+00
—
cases:0.00%
controls:1.24%
—
—
—
—
—
—
—
—
cases:5.38%
controls:0.45%
—
—
0
20
162
1589
—
—
—
—
7
7
123
1556
—
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
14933-6 [3026493]
3.2e-01
1.7e-01
—
—
2.5e+00
1.1e+00
-1.6e-01
cases:6.79%
controls:5.03%
cases:3.09%
controls:2.61%
—
—
—
—
cases:3.77%
controls:0.31%
cases:6.15%
controls:2.05%
cases:5.56%
controls:6.47%
11
81
151
1528
5
42
157
1567
—
—
6
5
153
1602
8
32
122
1531
5
88
85
1273
Periodontitis complex
K05.30 [2000502728]
K05.30 [2000502728]
—
-1.0e+50
—
—
—
2.5e+00
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
cases:4.62%
controls:0.38%
—
—
—
0
7
162
1602
—
—
—
6
6
124
1557
—
Counselling and guidance which enhance independent living
R2130 [2001310196]
R2130 [2001310196]
1.7e+00
—
—
—
—
2.5e+00
2.0e+00
cases:4.32%
controls:0.81%
—
—
—
—
—
—
—
—
cases:4.62%
controls:0.38%
cases:5.56%
controls:0.81%
7
13
155
1596
—
—
—
—
6
6
124
1557
5
11
85
1350
Physiotherapist
Z3226 [2001311560]
Z3226 [2001311560]
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
cases:3.85%
controls:0.32%
—
—
—
—
—
—
—
5
5
125
1558
—
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
2703-7 [3027801]
1.4e+00
—
—
—
1.0e+50
2.5e+00
1.0e+00
cases:3.70%
controls:0.93%
—
—
—
—
—
—
cases:3.14%
controls:0.00%
cases:3.85%
controls:0.32%
cases:7.78%
controls:2.94%
6
15
156
1594
—
—
—
5
0
154
1607
5
5
125
1558
7
40
83
1321
Gas panel - Capillary blood
24337-8 [3022313]
24337-8 [3022313]
—
-1.0e+50
—
—
—
2.5e+00
-1.0e+50
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
cases:3.85%
controls:0.32%
cases:0.00%
controls:0.96%
—
0
7
162
1602
—
—
—
5
5
125
1558
0
13
90
1348
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
2019-8 [3027946]
1.4e+00
—
—
—
1.0e+50
2.5e+00
1.0e+00
cases:3.70%
controls:0.93%
—
—
—
—
—
—
cases:3.14%
controls:0.00%
cases:3.85%
controls:0.32%
cases:7.78%
controls:2.94%
6
15
156
1594
—
—
—
5
0
154
1607
5
5
125
1558
7
40
83
1321
Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]
30313-1 [3002173]
—
—
—
—
—
2.5e+00
1.2e+00
—
—
—
—
—
—
—
—
—
—
cases:3.85%
controls:0.32%
cases:6.67%
controls:2.20%
—
—
—
—
—
5
5
125
1558
6
30
84
1331
Base excess in Arterial blood by calculation
1925-7 [3003396]
1925-7 [3003396]
1.5e+00
—
—
—
1.0e+50
2.5e+00
1.0e+00
cases:3.70%
controls:0.87%
—
—
—
—
—
—
cases:3.14%
controls:0.00%
cases:3.85%
controls:0.32%
cases:7.78%
controls:2.94%
6
14
156
1595
—
—
—
5
0
154
1607
5
5
125
1558
7
40
83
1321
Intraoral radiographic dental examination
EB1AA [2001301903]
EB1AA [2001301903]
7.7e-02
7.9e-01
2.5e+00
—
—
-8.1e-02
6.3e-01
cases:12.96%
controls:12.12%
cases:8.64%
controls:4.10%
cases:3.70%
controls:0.31%
—
—
—
—
cases:3.85%
controls:4.16%
cases:18.89%
controls:11.02%
21
195
141
1414
14
66
148
1543
6
5
156
1604
—
—
5
65
125
1498
17
150
73
1211
Rhinopharyngoscopy
UDH02 [2001301680]
UDH02 [2001301680]
—
2.5e+00
—
—
1.0e+50
—
—
—
—
cases:3.70%
controls:0.31%
—
—
—
—
cases:3.77%
controls:0.00%
—
—
—
—
—
6
5
156
1604
—
—
6
0
153
1607
—
—
hydrocortisone
S01BA02 [21603619]
S01BA02 [21603619]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.67%
controls:0.59%
—
—
—
—
—
—
6
8
84
1353
hydrocortisone
S01CB03 [21603666]
S01CB03 [21603666]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.67%
controls:0.59%
—
—
—
—
—
—
6
8
84
1353
Epistaxis
R04.0 [45606791]
R04.0 [45606791]
—
—
—
—
1.0e+50
—
2.5e+00
—
—
—
—
—
—
—
—
cases:5.66%
controls:0.00%
—
—
cases:8.89%
controls:0.81%
—
—
—
—
9
0
150
1607
—
8
11
82
1350
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
N02BE01 [21604344]
8.6e-02
4.2e-01
9.3e-01
—
1.2e+00
1.2e+00
4.8e-01
cases:30.25%
controls:28.46%
cases:22.84%
controls:16.28%
cases:8.64%
controls:3.60%
—
—
cases:12.58%
controls:4.04%
cases:41.54%
controls:17.02%
cases:45.56%
controls:34.09%
49
458
113
1151
37
262
125
1347
14
58
148
1551
—
20
65
139
1542
54
266
76
1297
41
464
49
897
enoxaparin; parenteral
B01AB05 [21600976]
B01AB05 [21600976]
8.1e-01
—
—
—
—
2.5e+00
—
cases:8.02%
controls:3.73%
—
—
—
—
—
—
—
—
cases:7.69%
controls:0.70%
—
—
13
60
149
1549
—
—
—
—
10
11
120
1552
—
Neurology
13 [38004458]
13 [38004458]
-3.1e-01
4.8e-01
2.4e+00
—
1.5e+00
—
-5.5e-02
cases:8.64%
controls:11.44%
cases:7.41%
controls:4.72%
cases:7.41%
controls:0.68%
—
—
cases:4.40%
controls:1.00%
—
—
cases:10.00%
controls:10.51%
14
184
148
1425
12
76
150
1533
12
11
150
1598
—
7
16
152
1591
—
9
143
81
1218
prednisolone; oral, parenteral
H02AB06 [21602734]
H02AB06 [21602734]
1.9e-01
4.6e-01
1.4e+00
—
1.6e+00
1.0e+00
8.8e-02
cases:12.35%
controls:10.44%
cases:9.26%
controls:6.03%
cases:6.17%
controls:1.62%
—
—
cases:4.40%
controls:0.93%
cases:14.62%
controls:5.69%
cases:13.33%
controls:12.34%
20
168
142
1441
15
97
147
1512
10
26
152
1583
—
7
15
152
1592
19
89
111
1474
12
168
78
1193
prednisolone
A07EA01 [21600653]
A07EA01 [21600653]
1.9e-01
4.5e-01
1.4e+00
—
1.6e+00
1.0e+00
8.2e-02
cases:12.35%
controls:10.44%
cases:9.26%
controls:6.09%
cases:6.17%
controls:1.62%
—
—
cases:4.40%
controls:0.93%
cases:14.62%
controls:5.69%
cases:13.33%
controls:12.42%
20
168
142
1441
15
98
147
1511
10
26
152
1583
—
7
15
152
1592
19
89
111
1474
12
169
78
1192
fluocinolone acetonide and antiinfectives
S02CA05 [21605177]
S02CA05 [21605177]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.56%
controls:0.51%
—
—
—
—
—
—
5
7
85
1354
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
14338-8 [3013742]
1.1e+00
-1.0e+50
—
—
—
2.4e+00
—
cases:3.09%
controls:1.06%
cases:0.00%
controls:0.68%
—
—
—
—
—
—
cases:9.23%
controls:0.90%
—
—
5
17
157
1592
0
11
162
1598
—
—
—
12
14
118
1549
—
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
J01CR02 [21602863]
2.5e-03
1.3e+00
—
—
—
2.4e+00
8.6e-01
cases:6.79%
controls:6.77%
cases:6.17%
controls:1.80%
—
—
—
—
—
—
cases:16.92%
controls:1.86%
cases:15.56%
controls:7.20%
11
109
151
1500
10
29
152
1580
—
—
—
22
29
108
1534
14
98
76
1263
General Surgery
2 [38004447]
2 [38004447]
5.2e-01
6.7e-01
2.4e+00
1.0e+50
1.1e+00
1.2e-01
2.4e-01
cases:27.16%
controls:18.21%
cases:10.49%
controls:5.66%
cases:6.17%
controls:0.62%
cases:3.70%
controls:0.00%
cases:3.14%
controls:1.06%
cases:6.92%
controls:6.21%
cases:18.89%
controls:15.50%
44
293
118
1316
17
91
145
1518
10
10
152
1599
6
0
156
1609
5
17
154
1590
9
97
121
1466
17
211
73
1150
Person consulting for explanation of investigation findings
Z71.2 [45552100]
Z71.2 [45552100]
-6.7e-02
—
—
—
2.3e+00
—
1.1e-01
cases:3.09%
controls:3.29%
—
—
—
—
—
—
cases:3.14%
controls:0.31%
—
—
cases:6.67%
controls:6.02%
5
53
157
1556
—
—
—
5
5
154
1602
—
6
82
84
1279
Pneumonia, unspecified
J18.9 [45601123]
J18.9 [45601123]
6.9e-01
1.1e+00
-1.0e+50
—
2.3e+00
7.5e-01
1.9e-01
cases:5.56%
controls:2.86%
cases:4.32%
controls:1.49%
cases:0.00%
controls:0.37%
—
—
cases:3.14%
controls:0.31%
cases:4.62%
controls:2.24%
cases:6.67%
controls:5.58%
9
46
153
1563
7
24
155
1585
0
6
162
1603
—
5
5
154
1602
6
35
124
1528
6
76
84
1285
Anaemia, unspecified
D64.9 [45600610]
D64.9 [45600610]
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
cases:3.85%
controls:0.38%
—
—
—
—
—
—
—
5
6
125
1557
—
Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection
54067-4 [3051552]
54067-4 [3051552]
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
cases:3.85%
controls:0.38%
—
—
—
—
—
—
—
5
6
125
1557
—
Extensive global examination
SPAT1360 [2001700461]
SPAT1360 [2001700461]
2.3e+00
—
—
—
—
—
-1.0e+50
cases:3.70%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
6
6
156
1603
—
—
—
—
—
0
7
90
1354
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood
47598-8 [3048816]
47598-8 [3048816]
7.9e-01
1.3e+00
—
—
—
2.3e+00
—
cases:3.09%
controls:1.43%
cases:4.32%
controls:1.18%
—
—
—
—
—
—
cases:10.00%
controls:1.09%
—
—
5
23
157
1586
7
19
155
1590
—
—
—
13
17
117
1546
—
Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection
13956-8 [3014162]
13956-8 [3014162]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.56%
controls:0.59%
—
—
—
—
—
—
5
8
85
1353
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
14879-1 [3003458]
1.2e+00
—
—
—
—
2.3e+00
1.2e+00
cases:5.56%
controls:1.80%
—
—
—
—
—
—
—
—
cases:10.77%
controls:1.22%
cases:8.89%
controls:2.79%
9
29
153
1580
—
—
—
—
14
19
116
1544
8
38
82
1323
EKG study
11524-6 [3013512]
11524-6 [3013512]
3.2e-02
-1.8e-01
1.4e+00
—
2.3e+00
8.8e-01
6.3e-02
cases:6.79%
controls:6.59%
cases:3.70%
controls:4.41%
cases:3.09%
controls:0.75%
—
—
cases:5.66%
controls:0.62%
cases:9.23%
controls:4.03%
cases:11.11%
controls:10.51%
11
106
151
1503
6
71
156
1538
5
12
157
1597
—
9
10
150
1597
12
63
118
1500
10
143
80
1218
valaciclovir; oral
J05AB11 [21603137]
J05AB11 [21603137]
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
cases:4.62%
controls:0.51%
—
—
—
—
—
—
—
6
8
124
1555
—
Fungus identified in Specimen by Culture
580-1 [3000494]
580-1 [3000494]
9.7e-01
1.3e+00
—
—
—
2.2e+00
8.6e-01
cases:4.32%
controls:1.68%
cases:3.70%
controls:0.99%
—
—
—
—
—
—
cases:4.62%
controls:0.51%
cases:5.56%
controls:2.42%
7
27
155
1582
6
16
156
1593
—
—
—
6
8
124
1555
5
33
85
1328
sodium fluoride; oral
A01AA01 [21600005]
A01AA01 [21600005]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.89%
controls:1.03%
—
—
—
—
—
—
8
14
82
1347
Carcinoembryonic Ag [Mass/volume] in Serum or Plasma
2039-6 [3003785]
2039-6 [3003785]
2.2e+00
—
—
—
—
—
—
cases:4.94%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
—
8
9
154
1600
—
—
—
—
—
—
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
2000-8 [3015377]
4.7e-01
1.1e+00
—
—
—
2.2e+00
8.8e-01
cases:6.79%
controls:4.35%
cases:6.79%
controls:2.30%
—
—
—
—
—
—
cases:16.15%
controls:2.05%
cases:14.44%
controls:6.54%
11
70
151
1539
11
37
151
1572
—
—
—
21
32
109
1531
13
89
77
1272
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
14675-3 [3036481]
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
cases:5.38%
controls:0.64%
—
—
—
—
—
—
—
7
10
123
1553
—
Other specified special examinations
Z01.8 [45581003]
Z01.8 [45581003]
—
2.2e+00
—
—
—
1.4e+00
8.3e-01
—
—
cases:6.17%
controls:0.75%
—
—
—
—
—
—
cases:3.85%
controls:1.02%
cases:5.56%
controls:2.50%
—
10
12
152
1597
—
—
—
5
16
125
1547
5
34
85
1327
Physiotherapy
R4110 [2001310233]
R4110 [2001310233]
-7.4e-02
—
—
—
—
2.1e+00
7.1e-01
cases:3.70%
controls:3.98%
—
—
—
—
—
—
—
—
cases:10.00%
controls:1.28%
cases:8.89%
controls:4.56%
6
64
156
1545
—
—
—
—
13
20
117
1543
8
62
82
1299
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
5894-1 [3033658]
5.5e-01
6.5e-01
—
—
—
2.1e+00
9.4e-01
cases:6.17%
controls:3.67%
cases:4.32%
controls:2.30%
—
—
—
—
—
—
cases:10.77%
controls:1.41%
cases:13.33%
controls:5.66%
10
59
152
1550
7
37
155
1572
—
—
—
14
22
116
1541
12
77
78
1284
Bacteria identified in Blood by Culture
600-7 [3023368]
600-7 [3023368]
2.6e-01
7.9e-01
2.1e+00
—
—
2.1e+00
6.4e-01
cases:4.32%
controls:3.36%
cases:4.94%
controls:2.30%
cases:3.09%
controls:0.37%
—
—
—
—
cases:16.92%
controls:2.37%
cases:11.11%
controls:6.17%
7
54
155
1555
8
37
154
1572
5
6
157
1603
—
—
22
37
108
1526
10
84
80
1277
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
1963-8 [3016293]
—
—
—
—
—
1.8e+00
2.0e+00
—
—
—
—
—
—
—
—
—
—
cases:3.85%
controls:0.64%
cases:7.78%
controls:1.10%
—
—
—
—
—
5
10
125
1553
7
15
83
1346
Infectious Disease
44 [38004484]
44 [38004484]
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
cases:4.62%
controls:0.64%
—
—
—
—
—
—
—
6
10
124
1553
—
Right side
ZXA00 [2001311346]
ZXA00 [2001311346]
5.5e-01
—
—
—
1.0e+50
2.0e+00
1.3e+00
cases:6.17%
controls:3.67%
—
—
—
—
—
—
cases:5.03%
controls:0.00%
cases:4.62%
controls:0.64%
cases:8.89%
controls:2.65%
10
59
152
1550
—
—
—
8
0
151
1607
6
10
124
1553
8
36
82
1325
fluconazole; oral, parenteral
J02AC01 [21603080]
J02AC01 [21603080]
2.1e-01
—
—
—
—
2.0e+00
8.6e-01
cases:5.56%
controls:4.54%
—
—
—
—
—
—
—
—
cases:10.00%
controls:1.47%
cases:7.78%
controls:3.45%
9
73
153
1536
—
—
—
—
13
23
117
1540
7
47
83
1314
pH of Specimen
17433-4 [3019225]
17433-4 [3019225]
—
—
—
—
—
2.0e+00
1.2e+00
—
—
—
—
—
—
—
—
—
—
cases:5.38%
controls:0.77%
cases:5.56%
controls:1.76%
—
—
—
—
—
7
12
123
1551
5
24
85
1337
Medical doctor
Z2221 [2001311556]
Z2221 [2001311556]
2.8e-01
—
—
—
—
1.9e+00
1.2e+00
cases:4.94%
controls:3.79%
—
—
—
—
—
—
—
—
cases:6.15%
controls:0.96%
cases:7.78%
controls:2.50%
8
61
154
1548
—
—
—
—
8
15
122
1548
7
34
83
1327
Pulmonary Disease
29 [38004472]
29 [38004472]
6.6e-01
7.8e-01
1.9e+00
—
1.3e+00
3.8e-01
5.0e-01
cases:15.43%
controls:8.64%
cases:9.26%
controls:4.47%
cases:4.94%
controls:0.81%
—
—
cases:3.14%
controls:0.87%
cases:6.15%
controls:4.29%
cases:15.56%
controls:10.07%
25
139
137
1470
15
72
147
1537
8
13
154
1596
—
5
14
154
1593
8
67
122
1496
14
137
76
1224
Removal of sutures
SPAT1153 [2001700254]
SPAT1153 [2001700254]
7.9e-01
—
—
—
—
1.8e+00
1.1e+00
cases:9.26%
controls:4.41%
—
—
—
—
—
—
—
—
cases:6.15%
controls:1.02%
cases:10.00%
controls:3.53%
15
71
147
1538
—
—
—
—
8
16
122
1547
9
48
81
1313
aciclovir; oral, parenteral
J05AB01 [21603131]
J05AB01 [21603131]
—
-1.0e+50
—
—
—
1.8e+00
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
cases:5.38%
controls:0.90%
—
—
—
0
11
162
1598
—
—
—
7
14
123
1549
—
sulfadiazine and trimethoprim
J01EE02 [21602962]
J01EE02 [21602962]
5.5e-01
—
—
—
—
1.8e+00
—
cases:4.32%
controls:2.55%
—
—
—
—
—
—
—
—
cases:5.38%
controls:0.90%
—
—
7
41
155
1568
—
—
—
—
7
14
123
1549
—
Optical coherence tomography (OCT) of ocular fundus
CK2X4 [2001301456]
CK2X4 [2001301456]
—
1.4e+00
—
—
—
—
1.8e+00
—
—
cases:3.09%
controls:0.75%
—
—
—
—
—
—
—
—
cases:7.78%
controls:1.32%
—
5
12
157
1597
—
—
—
—
7
18
83
1343
Emergency Medicine
93 [38004510]
93 [38004510]
-3.1e-01
4.8e-01
1.8e+00
—
1.2e+00
4.4e-01
3.5e-01
cases:9.26%
controls:12.18%
cases:11.11%
controls:7.21%
cases:6.17%
controls:1.06%
—
—
cases:3.14%
controls:1.00%
cases:10.00%
controls:6.65%
cases:25.56%
controls:19.54%
15
196
147
1413
18
116
144
1493
10
17
152
1592
—
5
16
154
1591
13
104
117
1459
23
266
67
1095
Thorax X-ray examination
GD1AA [2001303617]
GD1AA [2001303617]
3.5e-02
4.6e-01
1.7e+00
—
—
1.8e+00
8.0e-01
cases:8.02%
controls:7.77%
cases:4.94%
controls:3.17%
cases:3.09%
controls:0.56%
—
—
—
—
cases:15.38%
controls:2.88%
cases:15.56%
controls:7.64%
13
125
149
1484
8
51
154
1558
5
9
157
1600
—
—
20
45
110
1518
14
104
76
1257
Coloscopy
UJF32 [2001305029]
UJF32 [2001305029]
8.2e-01
—
—
—
—
1.8e+00
1.1e+00
cases:7.41%
controls:3.42%
—
—
—
—
—
—
—
—
cases:6.15%
controls:1.09%
cases:10.00%
controls:3.45%
12
55
150
1554
—
—
—
—
8
17
122
1546
9
47
81
1314
chloramphenicol
S02AA01 [21605147]
S02AA01 [21605147]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.78%
controls:1.40%
—
—
—
—
—
—
7
19
83
1342
chloramphenicol; ointment
D06AX02 [21602063]
D06AX02 [21602063]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.78%
controls:1.40%
—
—
—
—
—
—
7
19
83
1342
chloramphenicol
G01AA05 [21602367]
G01AA05 [21602367]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.78%
controls:1.40%
—
—
—
—
—
—
7
19
83
1342
chloramphenicol
D10AF03 [21602307]
D10AF03 [21602307]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.78%
controls:1.40%
—
—
—
—
—
—
7
19
83
1342
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
13317-3 [3019902]
—
—
2.3e+00
—
—
1.8e+00
—
—
—
—
—
cases:3.09%
controls:0.31%
—
—
—
—
cases:5.38%
controls:0.96%
—
—
—
—
5
5
157
1604
—
—
7
15
123
1548
—
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
22664-7 [3020779]
8.5e-01
—
—
—
—
1.8e+00
1.4e+00
cases:3.70%
controls:1.62%
—
—
—
—
—
—
—
—
cases:5.38%
controls:0.96%
cases:7.78%
controls:2.13%
6
26
156
1583
—
—
—
—
7
15
123
1548
7
29
83
1332
hypromellose
S01KA02 [21605115]
S01KA02 [21605115]
—
—
—
—
—
1.8e+00
1.4e+00
—
—
—
—
—
—
—
—
—
—
cases:5.38%
controls:0.96%
cases:6.67%
controls:1.76%
—
—
—
—
—
7
15
123
1548
6
24
84
1337
Acute maxillary sinusitis
J01.0 [45601112]
J01.0 [45601112]
—
1.6e+00
—
—
—
—
—
—
—
cases:5.56%
controls:1.12%
—
—
—
—
—
—
—
—
—
—
—
9
18
153
1591
—
—
—
—
—
Chronic apical periodontitis
K04.5 [45586691]
K04.5 [45586691]
5.7e-01
1.6e+00
—
—
—
1.6e+00
—
cases:5.56%
controls:3.23%
cases:3.70%
controls:0.75%
—
—
—
—
—
—
cases:6.15%
controls:1.28%
—
—
9
52
153
1557
6
12
156
1597
—
—
—
8
20
122
1543
—
azelastine; nasal
R01AC03 [21605035]
R01AC03 [21605035]
—
1.6e+00
—
—
—
-1.0e+50
—
—
—
cases:6.79%
controls:1.43%
—
—
—
—
—
—
cases:0.00%
controls:1.92%
—
—
—
11
23
151
1586
—
—
—
0
30
130
1533
—
fluticasone, combinations
R01AD58 [43534837]
R01AD58 [43534837]
—
1.6e+00
—
—
—
-1.0e+50
—
—
—
cases:6.79%
controls:1.43%
—
—
—
—
—
—
cases:0.00%
controls:1.92%
—
—
—
11
23
151
1586
—
—
—
0
30
130
1533
—
fluticasone; nasal
R01AD08 [21605050]
R01AD08 [21605050]
4.4e-01
1.6e+00
1.7e+00
—
—
4.5e-01
3.8e-01
cases:10.49%
controls:7.02%
cases:12.35%
controls:2.73%
cases:3.09%
controls:0.56%
—
—
—
—
cases:3.85%
controls:2.50%
cases:10.00%
controls:7.05%
17
113
145
1496
20
44
142
1565
5
9
157
1600
—
—
5
39
125
1524
9
96
81
1265
fluticasone furoate; nasal
R01AD12 [21605053]
R01AD12 [21605053]
4.4e-01
1.6e+00
1.7e+00
—
—
4.5e-01
3.8e-01
cases:10.49%
controls:7.02%
cases:12.35%
controls:2.73%
cases:3.09%
controls:0.56%
—
—
—
—
cases:3.85%
controls:2.50%
cases:10.00%
controls:7.05%
17
113
145
1496
20
44
142
1565
5
9
157
1600
—
—
5
39
125
1524
9
96
81
1265
levofloxacin
S01AE05 [43534860]
S01AE05 [43534860]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.00%
controls:2.35%
—
—
—
—
—
—
9
32
81
1329
Dental examination
Z01.2 [45581002]
Z01.2 [45581002]
4.1e-01
—
-1.0e+50
—
1.0e+50
1.5e+00
3.6e-01
cases:9.26%
controls:6.34%
—
—
cases:0.00%
controls:0.37%
—
—
cases:3.77%
controls:0.00%
cases:8.46%
controls:1.98%
cases:12.22%
controls:8.82%
15
102
147
1507
—
0
6
162
1603
—
6
0
153
1607
11
31
119
1532
11
120
79
1241
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
3016-3 [3009201]
1.4e-01
2.5e-01
1.1e+00
—
1.5e+00
4.5e-01
-1.3e-01
cases:24.07%
controls:21.63%
cases:16.05%
controls:12.93%
cases:4.32%
controls:1.43%
—
—
cases:5.66%
controls:1.31%
cases:20.00%
controls:13.76%
cases:28.89%
controls:31.67%
39
348
123
1261
26
208
136
1401
7
23
155
1586
—
9
21
150
1586
26
215
104
1348
26
431
64
930
Essential (primary) hypertension
I10 [45591453]
I10 [45591453]
3.1e-02
2.3e-01
1.1e+00
—
1.5e+00
6.3e-01
-3.7e-01
cases:17.28%
controls:16.84%
cases:11.73%
controls:9.57%
cases:4.32%
controls:1.55%
—
—
cases:5.66%
controls:1.31%
cases:16.15%
controls:9.34%
cases:17.78%
controls:23.88%
28
271
134
1338
19
154
143
1455
7
25
155
1584
—
9
21
150
1586
21
146
109
1417
16
325
74
1036
Telephone prescription or other care instructions
WZB00 [2001310884]
WZB00 [2001310884]
3.2e-01
—
—
—
—
—
1.5e+00
cases:4.32%
controls:3.17%
—
—
—
—
—
—
—
—
—
—
cases:12.22%
controls:3.01%
7
51
155
1558
—
—
—
—
—
11
41
79
1320
combinations of corticosteroids
D07AB30 [21602118]
D07AB30 [21602118]
3.9e-01
6.8e-01
—
—
—
1.5e+00
8.5e-01
cases:14.81%
controls:10.57%
cases:8.02%
controls:4.23%
—
—
—
—
—
—
cases:15.38%
controls:3.97%
cases:23.33%
controls:11.54%
24
170
138
1439
13
68
149
1541
—
—
—
20
62
110
1501
21
157
69
1204
combinations of corticosteroids
D07XB30 [21602188]
D07XB30 [21602188]
3.9e-01
6.8e-01
—
—
—
1.5e+00
8.5e-01
cases:14.81%
controls:10.57%
cases:8.02%
controls:4.23%
—
—
—
—
—
—
cases:15.38%
controls:3.97%
cases:23.33%
controls:11.54%
24
170
138
1439
13
68
149
1541
—
—
—
20
62
110
1501
21
157
69
1204
ketoprofen; oral, parenteral, rectal
M01AE03 [21603969]
M01AE03 [21603969]
9.2e-01
8.1e-01
-1.0e+50
—
—
1.5e+00
—
cases:10.49%
controls:4.47%
cases:3.70%
controls:1.68%
cases:0.00%
controls:0.37%
—
—
—
—
cases:6.92%
controls:1.66%
—
—
17
72
145
1537
6
27
156
1582
0
6
162
1603
—
—
9
26
121
1537
—
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
14771-0 [3018251]
3.6e-02
-1.3e-02
3.9e-01
—
1.4e+00
-2.1e-01
-1.9e-01
cases:26.54%
controls:25.85%
cases:15.43%
controls:15.60%
cases:3.70%
controls:2.55%
—
—
cases:6.92%
controls:1.74%
cases:15.38%
controls:18.36%
cases:32.22%
controls:36.52%
43
416
119
1193
25
251
137
1358
6
41
156
1568
—
11
28
148
1579
20
287
110
1276
29
497
61
864
cetirizine; oral
R06AE07 [21603497]
R06AE07 [21603497]
1.3e-01
1.3e+00
—
—
—
8.5e-01
3.0e-01
cases:7.41%
controls:6.59%
cases:7.41%
controls:2.11%
—
—
—
—
—
—
cases:5.38%
controls:2.37%
cases:7.78%
controls:5.88%
12
106
150
1503
12
34
150
1575
—
—
—
7
37
123
1526
7
80
83
1281
esomeprazole; oral, parenteral
A02BC05 [21600100]
A02BC05 [21600100]
2.2e-02
5.1e-01
—
—
1.5e+00
1.3e+00
3.3e-01
cases:6.79%
controls:6.65%
cases:6.17%
controls:3.79%
—
—
—
—
cases:4.40%
controls:1.06%
cases:11.54%
controls:3.52%
cases:10.00%
controls:7.42%
11
107
151
1502
10
61
152
1548
—
—
7
17
152
1590
15
55
115
1508
9
101
81
1260
zopiclone; oral
N05CF01 [21604654]
N05CF01 [21604654]
2.7e-01
4.4e-01
6.2e-01
—
1.2e+00
1.2e+00
5.1e-01
cases:11.11%
controls:8.70%
cases:8.64%
controls:5.72%
cases:3.09%
controls:1.68%
—
—
cases:4.40%
controls:1.31%
cases:14.62%
controls:5.05%
cases:14.44%
controls:9.18%
18
140
144
1469
14
92
148
1517
5
27
157
1582
—
7
21
152
1586
19
79
111
1484
13
125
77
1236
Simple examination of mouth
SAA01 [2001310274]
SAA01 [2001310274]
6.7e-02
4.8e-01
1.7e+00
—
—
1.1e+00
2.0e-01
cases:19.75%
controls:18.71%
cases:14.20%
controls:9.26%
cases:3.09%
controls:0.56%
—
—
—
—
cases:23.08%
controls:8.77%
cases:24.44%
controls:20.87%
32
301
130
1308
23
149
139
1460
5
9
157
1600
—
—
30
137
100
1426
22
284
68
1077
Caries of dentine
K02.1 [45548134]
K02.1 [45548134]
-1.7e-01
5.3e-02
-1.0e+50
—
—
9.6e-01
-7.2e-03
cases:10.49%
controls:12.18%
cases:5.56%
controls:5.28%
cases:0.00%
controls:0.62%
—
—
—
—
cases:13.85%
controls:5.82%
cases:15.56%
controls:15.65%
17
196
145
1413
9
85
153
1524
0
10
162
1599
—
—
18
91
112
1472
14
213
76
1148
pantoprazole; oral, parenteral
A02BC02 [21600097]
A02BC02 [21600097]
-2.7e-01
-7.5e-02
6.9e-01
—
8.1e-01
8.4e-01
-1.8e-01
cases:12.96%
controls:16.28%
cases:9.88%
controls:10.57%
cases:4.94%
controls:2.55%
—
—
cases:5.03%
controls:2.30%
cases:20.77%
controls:10.17%
cases:16.67%
controls:19.32%
21
262
141
1347
16
170
146
1439
8
41
154
1568
—
8
37
151
1570
27
159
103
1404
15
263
75
1098
ketotifen
S01GX08 [21605092]
S01GX08 [21605092]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.44%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
0
7
162
1602
—
—
—
—
—
0
5
90
1356
Influenza virus A Ag [Presence] in Nasopharynx by Immunoassay
46082-4 [3046524]
46082-4 [3046524]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.44%
cases:0.00%
controls:0.44%
—
—
—
—
—
—
—
—
—
—
0
7
162
1602
0
7
162
1602
—
—
—
—
—
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
14798-3 [3022948]
8.8e-01
—
-1.0e+50
—
—
—
1.8e-01
cases:4.94%
controls:2.11%
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
cases:5.56%
controls:4.70%
8
34
154
1575
—
0
11
162
1598
—
—
—
5
64
85
1297
Vertigo/dizziness
N17 [2002000728]
N17 [2002000728]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
0
6
162
1603
—
—
—
—
—
valsartan and amlodipine
C09DB01 [21601842]
C09DB01 [21601842]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
0
6
159
1601
—
—
Synovial cyst of popliteal space [Baker]
M71.2 [45596669]
M71.2 [45596669]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
0
8
162
1601
—
—
—
—
—
0
5
90
1356
ivermectin
D11AX22 [45893486]
D11AX22 [45893486]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
7
90
1354
intermediate-acting sulfonamides - combinations
J01EC20 [21602948]
J01EC20 [21602948]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.88%
—
—
—
—
—
—
0
12
90
1349
Periodontitis NOS
K05.32 [2000502730]
K05.32 [2000502730]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
162
1604
—
—
—
—
—
—
Gonarthrosis, unspecified
M17.9 [45606128]
M17.9 [45606128]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.76%
—
—
—
—
—
—
0
24
90
1337
Other dorsalgia
M54.8 [45538790]
M54.8 [45538790]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
90
1356
metformin and dapagliflozin
A10BD15 [43534751]
A10BD15 [43534751]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
90
1356
nebivolol; oral
C07AB12 [21601694]
C07AB12 [21601694]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
0
8
162
1601
—
—
—
—
—
0
5
90
1356
encephalitis, tick borne, inactivated, whole virus
J07BA01 [21601331]
J07BA01 [21601331]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.43%
cases:0.00%
controls:0.44%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.76%
0
23
162
1586
0
7
162
1602
—
—
—
—
0
24
90
1337
Gastroenteritis presumed infection
D73 [2002000371]
D73 [2002000371]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
7
90
1354
Tracheostomy
GBB00 [2001303560]
GBB00 [2001303560]
—
—
—
—
1.0e+50
1.0e+50
—
—
—
—
—
—
—
—
—
cases:3.77%
controls:0.00%
cases:3.85%
controls:0.00%
—
—
—
—
—
—
6
0
153
1607
5
0
125
1563
—
Homocysteine [Moles/volume] in Serum or Plasma
13965-9 [3016724]
13965-9 [3016724]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
0
6
162
1603
—
—
—
—
—
Type 2 diabetes mellitus, with renal complications
E11.2 [45605400]
E11.2 [45605400]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
14
90
1347
Dementia in Alzheimer disease, unspecified and Alzheimer disease, unspecified
F00.9*G30.9 [2000503852]
F00.9*G30.9 [2000503852]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
90
1356
Presence of coronary angioplasty implant and graft
Z95.5 [45542496]
Z95.5 [45542496]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.88%
—
—
—
—
—
—
0
12
90
1349
sulfasalazine; oral, rectal
A07EC01 [21600663]
A07EC01 [21600663]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.90%
—
—
—
—
—
—
—
0
14
130
1549
—
SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: Unspecified
SMOKING-2-3-0 [2002330113]
SMOKING-2-3-0 [2002330113]
-6.4e-01
—
-1.0e+50
—
—
1.0e+50
1.0e+50
cases:3.70%
controls:6.77%
—
—
cases:0.00%
controls:0.37%
—
—
—
—
cases:4.62%
controls:0.00%
cases:5.56%
controls:0.00%
6
109
156
1500
—
0
6
162
1603
—
—
6
0
124
1563
5
0
85
1361
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
UJD10 [2001304788]
-1.2e-01
—
—
—
—
—
—
cases:3.70%
controls:4.16%
—
—
—
—
—
—
—
—
—
—
—
—
6
67
156
1542
—
—
—
—
—
—
tiaprofenic acid; oral, rectal
M01AE11 [21603977]
M01AE11 [21603977]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
162
1603
—
—
—
—
—
—
Congestive heart failure
I50.0 [45567179]
I50.0 [45567179]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
0
10
130
1553
—
Sciatica
M54.3 [45586994]
M54.3 [45586994]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
0
12
162
1597
—
—
—
—
—
0
5
90
1356
bisoprolol and thiazides
C07BB07 [21601714]
C07BB07 [21601714]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.56%
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
0
9
162
1600
0
6
162
1603
—
—
—
—
—
Prostate specific Ag panel - Serum or Plasma
53764-7 [3039443]
53764-7 [3039443]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
0
5
162
1604
—
—
—
—
—
Mixed asthma
J45.8 [45548118]
J45.8 [45548118]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
162
1604
—
—
—
—
—
—
Check up of cardiac pacemaker
XFP20 [2001303367]
XFP20 [2001303367]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.62%
—
—
—
—
—
—
0
22
90
1339
Localized swelling, mass and lump, head
R22.0 [45548955]
R22.0 [45548955]
—
—
—
1.0e+50
1.0e+50
—
—
—
—
—
—
—
—
cases:3.09%
controls:0.00%
cases:3.77%
controls:0.00%
—
—
—
—
—
—
—
5
0
157
1609
6
0
153
1607
—
—
beclometasone; inhalant
R03BA01 [21603284]
R03BA01 [21603284]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
0
5
159
1602
—
—
Contusion of shoulder and upper arm
S40.0 [45563774]
S40.0 [45563774]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
0
5
162
1604
—
—
—
—
—
verapamil; oral, parenteral
C08DA01 [21601767]
C08DA01 [21601767]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
6
90
1355
tadalafil; oral
G04BE08 [21602653]
G04BE08 [21602653]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
cases:0.00%
controls:1.62%
—
—
—
—
—
0
12
130
1551
0
22
90
1339
Cardiac ultrasound examination through oesophagus
FM1BE [2001303285]
FM1BE [2001303285]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.88%
—
—
—
—
—
—
0
12
90
1349
Streptococcus pyogenes Ag [Presence] in Throat
18481-2 [3033319]
18481-2 [3033319]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
0
6
130
1557
—
sildenafil; oral
G04BE03 [21602648]
G04BE03 [21602648]
5.0e-01
—
—
—
—
—
—
cases:6.17%
controls:3.85%
—
—
—
—
—
—
—
—
—
—
—
—
10
62
152
1547
—
—
—
—
—
—
oxycodone and naloxone; oral
N02AA55 [21604265]
N02AA55 [21604265]
1.1e+00
—
—
—
—
—
—
cases:4.32%
controls:1.55%
—
—
—
—
—
—
—
—
—
—
—
—
7
25
155
1584
—
—
—
—
—
—
Tear of meniscus, current
S83.2 [45555441]
S83.2 [45555441]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
0
6
162
1603
—
—
—
—
—
0
8
90
1353
losartan; oral
C09CA01 [21601824]
C09CA01 [21601824]
4.7e-01
5.5e-01
—
—
—
4.7e-01
7.8e-01
cases:8.64%
controls:5.59%
cases:8.02%
controls:4.79%
—
—
—
—
—
—
cases:8.46%
controls:5.44%
cases:14.44%
controls:7.20%
14
90
148
1519
13
77
149
1532
—
—
—
11
85
119
1478
13
98
77
1263
Laparoscopy
JAH01 [2001304475]
JAH01 [2001304475]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
90
1356
scopolamine
A04AD01 [21600499]
A04AD01 [21600499]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
0
6
162
1603
—
—
—
—
—
Bicarbonate [Moles/volume] in Capillary blood
1961-2 [3015235]
1961-2 [3015235]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
0
5
162
1604
—
—
—
—
—
perindopril; oral
C09AA04 [21601788]
C09AA04 [21601788]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
0
10
90
1351
Albumin [Mass/volume] in Cerebral spinal fluid
1746-7 [3024474]
1746-7 [3024474]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
162
1604
—
—
—
—
—
—
acetylcysteine; inhalant, oral
R05CB01 [21603380]
R05CB01 [21603380]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
162
1604
—
—
—
—
—
—
formoterol, glycopyrronium bromide and beclometasone
R03AL09 [1502099]
R03AL09 [1502099]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
9
90
1352
Lyme disease
A69.2 [45595594]
A69.2 [45595594]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
162
1601
—
—
—
—
—
—
Examination of ears and hearing
Z01.1 [45547279]
Z01.1 [45547279]
1.3e+00
—
—
—
—
1.6e+00
1.0e+00
cases:4.32%
controls:1.18%
—
—
—
—
—
—
—
—
cases:4.62%
controls:0.96%
cases:5.56%
controls:2.06%
7
19
155
1590
—
—
—
—
6
15
124
1548
5
28
85
1333
Thrombin time
3243-3 [3036489]
3243-3 [3036489]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
0
5
162
1604
—
—
—
—
—
Treponema pallidum Ab [Titer] in Serum by Hemagglutination
26009-1 [3019539]
26009-1 [3019539]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
162
1603
—
—
—
—
—
—
Ultrasound examination of early pregnancy (before 12. postmenstrual week)
MA1AE [2001306827]
MA1AE [2001306827]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
162
1603
—
—
—
—
—
—
Endomysium IgA Ab [Titer] in Serum
10863-9 [3020961]
10863-9 [3020961]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
9
90
1352
Chronic glaucoma with open ventricular angle
H40.13 [2000502335]
H40.13 [2000502335]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.06%
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
0
17
162
1592
0
12
162
1597
—
—
—
—
—
Cytology report of Urine Cyto stain
47525-1 [3049717]
47525-1 [3049717]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
7
90
1354
hepatitis B, purified antigen
J07BC01 [21601338]
J07BC01 [21601338]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
162
1602
—
—
—
—
—
—
IgE [Units/volume] in Serum or Plasma
19113-0 [3005322]
19113-0 [3005322]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.67%
controls:1.62%
—
—
—
—
—
—
6
22
84
1339
haemophilus influenzae B and hepatitis B
J07CA08 [21601379]
J07CA08 [21601379]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
162
1604
—
—
—
—
—
—
Nonorganic insomnia
F51.0 [45552492]
F51.0 [45552492]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
cases:0.00%
controls:0.90%
cases:0.00%
controls:1.91%
—
0
13
162
1596
—
—
—
0
14
130
1549
0
26
90
1335
Iron deficiency anaemia secondary to blood loss (chronic)
D50.0 [45566697]
D50.0 [45566697]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
0
8
90
1353
Taking care of patient’s/customer’s hygiene
SPAT1137 [2001700238]
SPAT1137 [2001700238]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
5
162
1604
—
0
5
159
1602
—
—
Vomiting
D10 [2002000309]
D10 [2002000309]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
162
1602
—
—
—
—
—
—
Intravenous administration of medicine
SPAT1255 [2001700356]
SPAT1255 [2001700356]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
—
0
10
162
1599
—
—
—
—
—
Other difficulties with micturition
R39.1 [45534441]
R39.1 [45534441]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
0
6
130
1557
—
Simple extraction of IUD
TLC02 [2001306648]
TLC02 [2001306648]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
162
1604
—
—
—
—
—
—
Oxygen [Partial pressure] in Blood
11556-8 [3027315]
11556-8 [3027315]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.50%
cases:0.00%
controls:0.56%
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
0
8
162
1601
0
9
162
1600
—
—
—
0
8
130
1555
—
hydrocortisone
D07AA02 [21602102]
D07AA02 [21602102]
2.0e-01
-1.0e+50
-1.0e+50
—
-1.0e+50
1.1e+00
5.5e-01
cases:9.26%
controls:7.71%
cases:0.00%
controls:1.93%
cases:0.00%
controls:0.31%
—
—
cases:0.00%
controls:0.44%
cases:6.92%
controls:2.43%
cases:12.22%
controls:7.42%
15
124
147
1485
0
31
162
1578
0
5
162
1604
—
0
7
159
1600
9
38
121
1525
11
101
79
1260
Atrial fibrillation/flutter
K78 [2002000605]
K78 [2002000605]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
cases:0.00%
controls:1.25%
—
—
—
—
—
0
10
130
1553
0
17
90
1344
Vision screening
408760009 [4237318]
408760009 [4237318]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
90
1356
Extraction of multiple teeth
EBA15 [2001301927]
EBA15 [2001301927]
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:3.85%
controls:0.00%
—
—
—
—
—
—
—
5
0
125
1563
—
methylprednisolone
D07AA01 [21602101]
D07AA01 [21602101]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
162
1604
—
—
—
—
—
—
Heartburn
R12 [45539318]
R12 [45539318]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
cases:0.00%
controls:1.54%
—
—
—
—
—
0
5
130
1558
0
21
90
1340
donepezil; oral
N06DA02 [21604795]
N06DA02 [21604795]
-1.0e+50
-1.0e+50
-1.0e+50
—
-1.0e+50
—
—
cases:0.00%
controls:1.06%
cases:0.00%
controls:0.75%
cases:0.00%
controls:0.31%
—
—
cases:0.00%
controls:0.37%
—
—
—
—
0
17
162
1592
0
12
162
1597
0
5
162
1604
—
0
6
159
1601
—
—
Dementia in Alzheimer's disease, atypical or mixed type without additional symptoms
F00.20*G30.8 [2000501580]
F00.20*G30.8 [2000501580]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
7
90
1354
betamethasone
A07EA04 [21600656]
A07EA04 [21600656]
8.4e-02
—
-1.0e+50
—
-1.0e+50
—
—
cases:6.79%
controls:6.28%
—
—
cases:0.00%
controls:0.50%
—
—
cases:0.00%
controls:0.50%
—
—
—
—
11
101
151
1508
—
0
8
162
1601
—
0
8
159
1599
—
—
Moderate depressive episode without somatic syndrome
F32.10 [2000501980]
F32.10 [2000501980]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
162
1602
—
—
—
—
—
—
Sprain and strain of ankle
S93.4 [45550848]
S93.4 [45550848]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.68%
cases:0.00%
controls:0.31%
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
0
11
162
1598
0
5
162
1604
—
—
—
0
7
130
1556
—
Extraction of root of tooth
EBA30 [2001301929]
EBA30 [2001301929]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.12%
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
0
18
162
1591
0
6
162
1603
—
—
—
—
—
Intramuscular and subcutaneous injection
SPAT1256 [2001700357]
SPAT1256 [2001700357]
1.2e-01
5.0e-01
-1.0e+50
—
—
1.5e-01
5.2e-01
cases:9.26%
controls:8.27%
cases:6.79%
controls:4.23%
cases:0.00%
controls:0.62%
—
—
—
—
cases:5.38%
controls:4.67%
cases:13.33%
controls:8.38%
15
133
147
1476
11
68
151
1541
0
10
162
1599
—
—
7
73
123
1490
12
114
78
1247
Volume in Urine collected for unspecified duration
19153-6 [3004775]
19153-6 [3004775]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.44%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
0
7
162
1602
—
—
—
—
—
0
5
90
1356
mometasone, combinations
R01AD59 [947911]
R01AD59 [947911]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
9
90
1352
insulin glargine; parenteral
A10AE04 [21600739]
A10AE04 [21600739]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:2.55%
cases:0.00%
controls:0.50%
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
0
41
162
1568
0
8
162
1601
—
0
14
159
1593
—
—
Chlamydophila sp Ab [Presence] in Serum
46179-8 [3047007]
46179-8 [3047007]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
162
1604
—
—
—
—
—
—
SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay
96119-3 [36032419]
96119-3 [36032419]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
162
1602
—
—
—
—
—
—
Upper gastrointestinal surgery
106 [44777669]
106 [44777669]
5.7e-01
5.0e-01
—
—
—
9.9e-01
9.3e-01
cases:14.81%
controls:8.95%
cases:6.17%
controls:3.85%
—
—
—
—
—
—
cases:8.46%
controls:3.33%
cases:17.78%
controls:7.86%
24
144
138
1465
10
62
152
1547
—
—
—
11
52
119
1511
16
107
74
1254
adalimumab; parenteral
L04AB04 [21603911]
L04AB04 [21603911]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.56%
cases:0.00%
controls:0.50%
—
—
—
—
—
—
cases:0.00%
controls:0.51%
cases:0.00%
controls:0.81%
0
9
162
1600
0
8
162
1601
—
—
—
0
8
130
1555
0
11
90
1350
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
32
99
3.72
9.15
2.5
2.0
0.24
0.20
g/l
1.64
32
81
14
12
12.55
8.23
1.1
1.0
—
—
—
0
0
95
569
2.45
7.86
6.6
3.5
32.84
35.57
g/l
3.67
88
520
105
685
2.31
6.81
10.8
6.1
1.21
1.21
mmol/l
0.02
87
597
90
558
2.25
6.51
4.2
2.4
—
—
estimate
—
0
0
38
162
2.71
6.28
8.3
7.5
0.93
1.26
mmol/l
0.15
30
138
75
440
2.22
6.12
6.5
2.0
2.36
2.35
mmol/l
0.31
70
378
93
597
2.18
6.03
8.8
5.7
1.20
1.21
mmol/l
0.29
84
540
104
704
2.16
5.82
19.7
6.1
3.85
4.20
e9/l
0.92
95
611
55
291
2.29
5.70
3.3
1.9
—
—
—
0
0
14
27
5.54
5.20
2.5
3.1
1.14
1.96
mg/l
2.87
14
21
14
29
5.15
4.93
1.6
1.2
—
—
—
0
0
7
5
14.49
4.61
4.9
9.6
—
—
—
0
0
10
16
6.55
4.36
1.2
1.3
—
—
—
0
0
15
47
3.39
4.16
1.5
3.9
—
—
—
0
0
11
23
5.03
3.94
1.9
1.3
—
—
—
0
0
104
1288
0.53
3.93
6.1
5.3
6.04
6.08
mmol/l
0.14
94
1170
107
800
1.85
3.84
7.5
4.5
6.87
6.84
mmol/l
0.07
100
756
105
1292
0.54
3.78
5.0
5.5
4.68
4.48
mmol/l
0.90
98
1200
33
573
0.48
3.63
1.8
2.0
1.25
1.31
mmol/l
0.23
24
479
108
1313
0.54
3.62
5.6
6.3
2.73
2.59
mmol/l
0.60
99
1212
105
1286
0.55
3.59
5.1
5.4
1.44
1.43
mmol/l
0.05
97
1186
11
26
4.44
3.57
5.2
2.2
25.45
9.86
u/ml
1.22
11
16
21
95
2.37
3.04
1.3
1.7
—
—
—
0
0
10
27
3.86
2.93
2.2
2.0
85.40
88.15
%
—
10
27
102
1232
0.59
2.84
4.7
4.6
1.30
1.29
mmol/l
0.08
91
1129
26
133
2.12
2.83
5.0
3.3
—
—
—
0
0
5
6
8.53
2.76
1.8
1.0
—
—
—
0
0
6
10
6.16
2.72
3.0
2.2
—
—
—
0
0
9
24
3.89
2.71
1.6
1.0
—
—
—
0
0
106
1259
0.61
2.61
6.9
7.1
40.00
40.34
mmol/mol
0.14
96
1172
8
20
4.14
2.60
1.6
1.1
—
—
—
0
0
5
7
7.31
2.56
2.2
1.6
16.67
15.54
ug/l
—
5
7
6
11
5.60
2.56
1.5
1.2
—
—
—
0
0
65
472
1.60
2.25
2.8
3.0
—
—
—
0
0
8
24
3.44
2.21
2.0
2.2
202.63
189.63
%
—
8
24
7
19
3.79
2.17
1.4
1.1
—
—
—
0
0
8
25
3.30
2.12
2.8
1.2
—
—
—
0
0
8
25
3.30
2.12
2.9
1.2
—
—
—
0
0
6
15
4.10
2.05
3.3
1.4
—
—
—
0
0
6
15
4.10
2.05
1.0
1.1
—
—
—
0
0
6
15
4.10
2.05
1.0
1.0
—
—
—
0
0
11
44
2.60
2.05
4.4
1.2
68.62
33.57
mg/l
0.46
11
39
5
12
4.25
1.83
2.2
1.3
—
—
—
0
0
51
368
1.54
1.76
2.8
2.9
0.27
0.40
e6/l
0.36
40
263
8
30
2.74
1.74
1.8
1.2
—
—
—
0
0
5
13
3.92
1.72
1.4
1.2
—
—
—
0
0
5
13
3.92
1.72
1.4
1.2
—
—
—
0
0
5
13
3.92
1.72
1.4
1.2
—
—
—
0
0
7
25
2.87
1.66
1.6
1.3
—
—
—
0
0
19
106
1.89
1.66
4.1
2.1
70.80
64.34
ml/min/173m2
—
10
38
5
14
3.64
1.62
1.4
1.2
—
—
—
0
0
5
14
3.64
1.62
1.4
1.2
—
—
—
0
0
5
14
3.64
1.62
1.4
1.2
—
—
—
0
0
6
20
3.07
1.59
1.0
1.1
—
—
—
0
0
10
44
2.35
1.58
4.7
1.2
29.75
50.56
mg/l
—
10
39
39
536
0.65
1.56
6.5
4.2
7.21
7.01
mg/mmol
0.02
27
358
12
58
2.15
1.53
1.1
1.0
—
—
—
0
0
108
1222
0.70
1.45
7.4
5.0
2.36
1.95
mu/l
1.32
97
1107
50
375
1.46
1.42
2.0
2.2
2.88
2.84
mg/l
0.04
41
316
14
76
1.91
1.34
2.0
1.4
—
—
—
0
0
5
18
2.83
1.29
1.0
1.3
61.80
60.58
pmol/l
—
5
18
8
35
2.35
1.28
1.6
1.2
68.00
5.48
e6/l
—
8
27
8
36
2.28
1.26
1.6
1.3
4649.13
3438.86
e6/l
—
8
28
8
36
2.28
1.26
1.3
1.4
—
—
—
0
0
20
125
1.68
1.24
2.2
2.4
0.49
0.44
e6/l
0.07
20
116
7
31
2.31
1.11
1.9
2.1
—
—
—
0
0
17
105
1.68
1.11
3.4
2.0
66.46
67.65
g/l
0.32
17
97
25
171
1.54
1.10
2.7
1.7
—
—
—
0
0
38
290
1.40
0.98
3.3
4.5
147.28
375.99
ng/l
0.63
32
234
32
239
1.41
0.93
2.8
1.7
—
—
—
0
0
15
225
0.64
0.89
1.5
1.3
13.24
10.90
u/ml
—
5
88
25
337
0.70
0.88
3.4
2.8
0.68
0.80
ug/l
0.42
17
218
50
603
0.76
0.86
5.3
4.2
1.74
1.98
ug/l
0.52
45
533
95
842
1.28
0.85
4.1
4.5
67.60
281.79
e6/l
—
5
14
8
47
1.73
0.82
4.5
1.2
12.11
10.15
g/l
—
8
41
56
660
0.78
0.80
2.3
2.1
86.94
96.94
pmol/l
1.02
37
344
28
211
1.39
0.78
2.3
2.7
1.76
2.61
e6/l
0.34
19
103
13
194
0.64
0.76
4.4
5.0
29.13
31.93
%
—
8
123
9
56
1.64
0.73
2.0
3.2
26.40
24.83
mmol/l
—
9
51
25
187
1.39
0.73
2.7
1.7
—
—
—
0
0
36
286
1.32
0.73
1.8
1.6
1.12
1.15
mg/l
0.04
29
220
13
85
1.57
0.71
1.4
1.3
107.32
622.14
u/ml
0.94
13
80
12
178
0.65
0.69
13.3
6.8
—
—
—
0
0
5
30
1.69
0.62
1.0
1.2
—
—
—
0
0
21
274
0.73
0.62
1.2
1.3
0.83
0.97
u/ml
—
7
90
0
20
0.00
0.60
0.0
1.2
—
20.40
—
0
5
0
23
0.00
0.58
0.0
3.5
—
27.50
—
0
10
13
90
1.48
0.57
1.8
2.8
4.27
1.68
mmol/l
—
6
60
8
122
0.64
0.57
2.3
2.3
3.32
3.34
ratio
—
8
105
32
261
1.28
0.55
1.6
1.8
1015.42
1147.79
nmol/l
0.37
24
206
7
45
1.58
0.49
5.0
1.3
0.00
0.00
g/l
—
7
39
7
45
1.58
0.49
2.4
1.4
—
—
—
0
0
65
722
0.84
0.48
2.9
2.5
—
—
—
0
0
7
48
1.48
0.47
3.7
1.6
—
—
—
0
0
64
708
0.85
0.44
4.3
3.8
0.00
0.00
estimate
-0.00
17
131
6
94
0.63
0.43
1.5
1.4
—
—
—
0
0
56
499
1.18
0.42
2.7
3.4
653.15
1670.41
ng/l
4.09
48
430
8
59
1.37
0.41
4.5
1.3
3.22
3.70
g/l
—
8
53
8
59
1.37
0.41
4.5
1.3
7.17
7.56
g/l
—
8
53
8
59
1.37
0.41
4.5
1.3
3.87
4.37
g/l
—
8
53
64
702
0.86
0.39
4.3
3.8
0.00
0.00
estimate
-0.00
17
138
42
476
0.85
0.38
6.0
3.8
24.82
24.49
%
0.04
19
222
11
81
1.38
0.37
2.5
1.5
—
—
—
0
0
6
47
1.29
0.32
1.5
1.3
—
—
—
0
0
35
307
1.17
0.32
2.2
1.9
336.97
401.75
pmol/l
1.53
30
255
11
142
0.76
0.32
1.3
1.4
—
—
—
0
0
64
692
0.88
0.31
4.2
3.8
0.00
0.00
estimate
-0.00
15
136
103
1080
0.89
0.29
35.3
18.7
330.44
332.31
g/l
1.17
103
1070
36
402
0.87
0.27
5.2
3.6
0.00
0.00
estimate
-0.00
16
123
64
597
1.11
0.24
2.5
2.4
76.71
77.21
nmol/l
0.05
57
540
13
106
1.24
0.24
1.9
2.8
5.09
4.92
kpa
0.49
13
101
132
1358
0.89
0.23
33.9
18.2
3.96
4.01
mmol/l
1.25
127
1311
26
230
1.15
0.22
2.0
2.6
1.33
0.92
e6/l
0.33
15
121
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
4.00
—
0
7
0
14
0.00
0.20
0.0
1.0
—
39.66
—
0
8
0
14
0.00
0.20
0.0
1.0
—
623.22
—
0
9
7
58
1.22
0.18
5.0
1.3
3.47
2.89
g/l
—
7
52
133
1298
1.10
0.18
31.0
14.3
29.78
25.62
mg/l
0.76
126
1028
63
597
1.09
0.17
2.3
2.9
176.37
122.21
ug/l
0.88
57
555
58
610
0.93
0.15
3.8
4.1
31.27
100.68
ng/l
0.71
45
464
10
113
0.88
0.08
2.1
1.4
—
—
—
0
0
123
1248
0.95
0.07
29.5
14.0
81.14
76.15
ml/min/173m2
1.98
117
1153
14
128
1.10
0.07
4.7
2.5
4.34
4.51
kpa
0.18
14
121
39
375
1.05
0.06
5.1
3.3
0.00
0.00
estimate
-0.00
14
105
52
536
0.96
0.06
4.3
3.7
0.00
0.00
estimate
-0.00
11
111
41
424
0.96
0.05
2.0
1.8
15.74
19.87
nmol/l
1.15
32
368
99
1001
0.98
0.03
6.3
3.9
14.32
14.90
pmol/l
1.39
91
920
103
1038
0.98
0.01
38.6
17.6
14.30
13.67
%
3.97
103
1020
32
316
1.02
0.00
2.7
4.2
1.02
1.02
kg/l
0.38
27
202
18
181
0.99
0.00
1.3
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
39.98
—
0
8
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
2.15
—
0
7
0
5
0.00
-0.00
0.0
3.4
—
13.94
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
4.9
—
18.21
—
0
8
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
26.51
—
0
5
0
5
0.00
-0.00
0.0
1.4
—
55.61
—
0
5
8
84
0.95
-0.00
2.6
2.2
0.81
1.06
%
—
8
84
Mortality – FinRegistry
↥This endpoint is excluded (different definition than used in FinnGen).
Relationships between endpoints
↥Index endpoint: C3_ACCESSORY_SINUS_WIDE – Malignant neoplasm of accessory sinuses, including Hilmo
GWS hits: -
This endpoint is excluded (different definition than used in FinnGen).